What changed in this filing

/stocks — the workspaceLOADING

Item 8. Financial Statements and Supplementary Data

2026-05-20 compared with 2025-05-21 · 704 added, 476 removed, 1225 unchanged (49% of the section changed)

3 unchanged sentences

2026 March 29,

2024 April 1,

2025 March 30,

(Dollars in Thousands, except Per Share Data)

7 unchanged sentences

Remeasurement of contingent consideration ( 1,879 ) ( 23,022 ) —

Gains on divestiture and sale of assets — ( 2,000 ) ( 382 )

Impairment of intangible assets 86,546 2,391 10,419

5 unchanged sentences

Net income $ 97,308 $ 167,679 $ 117,558

Net income per share – basic $ 3.33 $ 2.32 $ 2.27

Net income per share – diluted $ 3.31 $ 2.29 $ 2.24

Net income per share:

Basic $ 2.06 $ 3.33 $ 2.32

Diluted $ 2.05 $ 3.31 $ 2.29

Weighted average shares outstanding

5 unchanged sentences

2026 March 29,

2024 April 1,

2025 March 30,

(Dollars in Thousands)

5 unchanged sentences

Reclassifications into earnings of cash flow hedge (gains) losses, net of tax ( 1,140 ) 56 ( 3,497 )

Other comprehensive (loss) income ( 19,452 ) ( 5,251 ) ( 4,427 )

Other comprehensive income (loss) 17,470 ( 19,452 ) ( 5,251 )

Comprehensive income $ 114,778 $ 148,227 $ 112,307

6 unchanged sentences

Cash and cash equivalents $ 245,440 $ 306,763

Accounts receivable, less allowance for credit losses of $ 6,300 at March 29, 2025 and $ 5,695 at March 30, 2024

Accounts receivable, less allowance for credit losses of $ 3,693 as of March 28, 2026 and $ 6,300 as of March 29, 2025

216,855 202,657

3 unchanged sentences

Property, plant and equipment, net 305,761 284,052

Intangible assets, less accumulated amortization of $ 316,313 at March 29, 2025 and $ 455,213 at March 30, 2024

Intangible assets, less accumulated amortization of $ 363,763 as of March 28, 2026 and $ 316,313 as of March 29, 2025

447,655 455,743

16 unchanged sentences

Authorized — 150,000,000 shares;

Issued and outstanding — 48,215,899 shares at March 29, 2025 and 50,787,859 shares at March 30, 2024

Issued and outstanding — 45,252,667 shares as of March 28, 2026 and 48,215,899 shares as of March 29, 2025

Additional paid-in capital 554,137 523,264

8 unchanged sentences

Paid-in Capital Retained Earnings Accumulated

Comprehensive Income/(Loss) Total

Comprehensive Loss Total

Stockholders’ Equity

4 unchanged sentences

Exercise of stock options 163,064 2 6,816 ( 5,208 ) — 1,610

Shares repurchased ( 997 ) ( 10 ) ( 10,366 ) ( 64,624 ) — ( 75,000 )

Issuance of restricted stock, net of cancellations 166,193 2 ( 2 ) — — —

Tax withholding on employee equity awards ( 68,944 ) ( 1 ) ( 828 ) ( 5,062 ) — ( 5,891 )

Share-based compensation expense — — 28,332 — — 28,332

Net income — — — 117,558 — 117,558

Other comprehensive income — — — — ( 4,427 ) ( 4,427 )

Balance, April 1, 2023 50,449 $ 504 $ 594,706 $ 253,168 $ ( 30,381 ) $ 817,997

Other comprehensive loss — — — — ( 5,251 ) ( 5,251 )

Balance, March 30, 2024 50,788,000 $ 508 $ 634,627 $ 360,456 $ ( 35,632 ) $ 959,959

Employee stock purchase plan 97,092 — 6,476 — — 6,476

Exercise of stock options 91,735 1 6,637 ( 4,781 ) — 1,857

Shares repurchased, including excise tax ( 3,030,887 ) ( 30 ) ( 64,533 ) ( 162,285 ) — ( 226,848 )

Issuance of restricted stock, net of cancellations 305,806 3 ( 3 ) — — —

Tax withholding on employee equity awards ( 35,847 ) — ( 1,376 ) ( 8,895 ) — ( 10,271 )

Purchase of capped call related to convertible notes — — ( 88,200 ) — — ( 88,200 )

Share-based compensation expense — — 29,636 — — 29,636

7 unchanged sentences

Tax withholding on employee equity awards ( 18,246 ) — ( 790 ) ( 3,893 ) — ( 4,683 )

Purchase of capped call related to convertible notes — — ( 88,200 ) — — ( 88,200 )

Share-based compensation expense — — 33,827 — — 33,827

Net income — — — 97,308 — 97,308

Other comprehensive loss — — — — ( 19,452 ) ( 19,452 )

Other comprehensive income — — — — 17,470 17,470

Balance, March 28, 2026 45,252,667 $ 453 $ 554,137 $ 279,344 $ ( 37,614 ) $ 796,320

3 unchanged sentences

2026 March 29,

2024 April 1,

2025 March 30,

(Dollars in Thousands)

28 unchanged sentences

Proceeds from issuance of convertible notes — 700,000 —

Repurchase of convertible senior notes ( 185,500 ) — —

Repayment and repurchase of convertible notes ( 300,000 ) ( 185,500 ) —

Purchase of capped call related to convertible notes — ( 88,200 ) —

5 unchanged sentences

Debt issuance costs — ( 23,135 ) —

Contingent consideration payments — ( 849 ) ( 21,593 )

Proceeds from employee stock programs 7,893 8,333 7,214

2 unchanged sentences

Other financing activities ( 102 ) ( 249 ) ( 922 )

Net cash provided by (used in) financing activities 108,818 38,157 ( 100,364 )

Net cash (used in) provided by financing activities ( 178,460 ) 108,818 38,157

Effect of exchange rates on cash and cash equivalents 3,463 ( 685 ) ( 3,185 )

2 unchanged sentences

Cash and Cash Equivalents at End of Year $ 245,440 $ 306,763 $ 178,800

The accompanying notes are an integral part of these consolidated financial statements.

HAEMONETICS CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

2026 March 29,

2025 March 30,

(Dollars in Thousands)

Supplemental Disclosures of Cash Flow Information:

1 unchanged sentence

Income taxes paid $ 60,665 $ 49,293 $ 52,706

Fair value of previously held equity interest settled in connection with acquisition $ 47,258 $ — $ —

Settlement of pre-existing loan in connection with acquisition $ 35,812 $ — $ —

The accompanying notes are an integral part of these consolidated financial statements.

3 unchanged sentences

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care.

Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients;

Haemonetics’ innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients;

end-to-end plasma collection technologies to optimize operations for plasma centers;

11 unchanged sentences

dollars, unless otherwise indicated.

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

Subsequent events have been evaluated as required.

There were no material recognized or unrecognized subsequent events except as described in Note 7, Earnings per Share and Note 5, Restructuring .

There were no material recognized or unrecognized subsequent events .

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

4 unchanged sentences

All significant intercompany accounts and transactions have been eliminated in consolidation.

In addition, we assess our strategic investments to determine whether they meet the definition of a variable interest entity (“VIE”), and if so, whether the Company has controlling financial interest.

In addition, the Company assesses its strategic investments to determine whether they meet the definition of a variable interest entity (“VIE”), and if so, whether the Company has controlling financial interest.

Controlling financial interest occurs if the Company has both the power to direct activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses of or the right to receive benefits from the VIE that could potentially be significant to the VIE.

30 unchanged sentences

For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation.

In software contracts with multiple performance obligations, we account for individual performance obligations separately if they are distinct.

We allocate the transaction price to each performance obligation based on our relative standalone selling price out of total consideration of the contract.

In software contracts with multiple performance obligations, the Company accounts for individual performance obligations separately if they are distinct.

The Company allocates the transaction price to each performance obligation based on its relative standalone selling price out of total consideration of the contract.

Standalone selling price is determined utilizing observable prices to the extent available.

If the standalone selling price for a performance obligation is not directly observable, we estimate it maximizing the use of observable inputs.

For maintenance and support, we determine the standalone selling price based on the price at which we separately sell a renewal contract and the economic relationship between licenses and maintenance.

If the standalone selling price for a performance obligation is not directly observable, the Company estimates it maximizing the use of observable inputs.

For maintenance and support, the Company determines the standalone selling price based on the price at which we separately sell a renewal contract and the economic relationship between licenses and maintenance.

Product Revenues

39 unchanged sentences

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year.

The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders’ equity.

The net effect of these translation adjustments is shown in the accompanying consolidated financial statements as a component of stockholders’ equity.

Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of income.

The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss on the consolidated balance sheet.

The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss (“AOCL”) on the consolidated balance sheets.

HAEMONETICS CORPORATION AND SUBSIDIARIES

27 unchanged sentences

The Company’s installed base of devices includes devices owned by the Company and devices sold to the customer.

The asset on its balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics.

Generally, the customer has the right to use it for a period of time as long as they meet the conditions the Company has established, which among other things, generally include one or more of the following:

• Purchase and consumption of a certain level of disposable products

• Payment of monthly rental fees

• An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted below for other intangible assets subject to amortization, the Company reviews Haemonetics equipment and the related useful lives of such equipment at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The asset on its consolidated balance sheets classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics.

Generally, the customer has the right to use it for a period of time during which they separately purchase disposables.

To conduct these reviews, the Company estimates the future amount and timing of demand for disposables used with these devices, from which it generates revenues.

2 unchanged sentences

Any significant unanticipated changes in demand could impact the value of the Company’s devices and its reported operating results.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease.

20 unchanged sentences

The Company allocates assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

In addition, when performing a quantitative test, the Company uses the income approach, specifically the discounted cash flow method, to derive the fair value of each of its reporting units in preparing its goodwill impairment assessments.

In addition, when performing a quantitative test, the Company primarily uses the income approach, specifically the discounted cash flow method, to derive the fair value of each of its reporting units in preparing its goodwill impairment assessments.

This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate.

8 unchanged sentences

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

During the fourth quarters of fiscal 2025 and 2023, the Company elected to perform quantitative assessments for its annual impairment test, whereas in fiscal 2024, the Company performed a qualitative assessment.

In fiscal 2025, 2024 and 2023, the results of the goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values and there were no reporting units at risk of impairment as of the annual test dates.

The Company reviews intangible assets subject to amortization for impairment indicators at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required.

Conditions indicating that an impairment exists include, but are not limited to, a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for its products or the size of the market for its products.

When an impairment indicator exists, the Company tests the intangible asset for recoverability.

Annual Goodwill Impairment Test

In fiscal 2026 the Company elected to perform the annual goodwill impairment test using qualitative assessments for three reporting units and a quantitative assessment for one reporting unit for its annual goodwill impairment test.

In fiscal 2025, the Company elected to perform quantitative assessments for its annual goodwill impairment test.

In fiscal 2024, the Company performed a qualitative assessment.

In fiscal 2026, 2025 and 2024, the results of the annual goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values, however, in fiscal 2026 the fair value of the Interventional Technologies reporting unit, which is within the Hospital reportable segment, was $ 867.8 million, which only exceeded its carrying value of $ 821.6 million by 6 %.

The fair value of the Interventional Technologies reporting unit was primarily determined using a discounted cash flow approach utilizing a discount rate of 10.5 %, which reflects a market-participant weighted average cost of capital based on the risk profile, size, and capital structure of the reporting unit.

The estimation of fair value requires significant judgment and is based primarily on a discounted cash flow approach, supplemented by market-based methods where appropriate.

Key assumptions include projected revenue growth rates, operating margins, and the discount rate.

These inputs are based on management’s expectations of future performance and market conditions and are inherently uncertain.

The Interventional Technologies reporting unit remains sensitive to changes in key assumptions.

A decline in projected revenue growth rates, or an increase in the discount rate, could result in the carrying value exceeding fair value.

The Company monitors for goodwill impairment indicators throughout the year, including changes in macroeconomic conditions, industry trends, and business performance.

No interim goodwill impairment indicators for the Interventional Technologies reporting unit were identified during fiscal 2026 that required an additional goodwill impairment test.

Although no goodwill impairment was recorded for the Interventional Technologies reporting unit during fiscal 2026, it remains at risk of future impairment if actual results differ from current estimates or if market conditions deteriorate.

Ongoing Monitoring of Long-Lived Intangible Asset Impairment

The Company also evaluates long-lived intangible assets subject to amortization for intangible impairment quarterly to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required.

Conditions indicating that an intangible impairment exists include but are not limited to a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for the Company’s products or the size of the market for the Company’s products.

Recoverability is assessed by comparing the carrying value of the asset group to the undiscounted cash flows expected to result from its use and eventual disposition.

If the carrying value exceeds those undiscounted cash flows, an intangible impairment loss is measured as the excess of carrying value over fair value.

When an intangible impairment indicator exists, the Company tests the intangible asset for recoverability.

For purposes of the recoverability test, the Company groups its amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities.

1 unchanged sentence

The Company generally calculates the fair value of its intangible assets as the present value of estimated future cash flows it expects to generate from the asset using a risk-adjusted discount rate.

In determining its estimated future cash flows associated with its intangible assets, the Company uses estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

In determining its estimated future cash flows associated with its intangible assets, the Company uses estimates and assumptions regarding future revenues, operating margins, customer attrition, economic conditions and remaining useful lives of the asset (asset group).

If the Company determines the estimate of an intangible asset’s remaining useful life should be reduced based on its expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

The Company had in-process research and development (“IPR&D”) intangible assets with indefinite lives.

IPR&D assets were not amortized prior to being placed in service in fiscal 2025.

Prior to amortization, the Company reviewed these assets for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of the asset is less than its carrying value.

The Company performed its annual impairment test on the first day of the fiscal fourth quarter for its IPR&D assets.

The Company made assumptions about future cash flows, terminal value growth, costs for completion and appropriate discount rates.

The Company elected qualitative assessments in fiscal 2025 and 2024, which all indicated that the estimated fair value of the in-process research and development intangible asset exceeded its carrying value and it was not at risk of impairment as of the annual test dates.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In the fourth quarter of fiscal 2026, the Company identified intangible impairment indicators related to the Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”) asset group within the Interventional Technologies reporting unit, which is within the Hospital reportable segment, including lower revenue projections, changes in market conditions and declines in operating performance.

As a result, a recoverability test was performed as of the first day of the fourth quarter in fiscal 2026 for the Attune Medical asset group and it was determined that the carrying value of the asset group exceeded the estimated undiscounted cash flows, indicating that the asset group was not recoverable.

As a result, an additional fair value measurement was performed for the Attune Medical asset group.

The fair value of the Attune Medical asset group was measured using a discounted cash flow approach.

As of the first day of the fourth quarter in fiscal 2026, the estimated fair value of the asset group was approximately $ 12.3 million, compared to a carrying value of $ 89.5 million, resulting in the recognition of an intangible impairment charge of $ 77.2 million in the fourth quarter of fiscal 2026.

Significant unobservable inputs used in the fair value measurement included projected revenues, operating margins, and a discount rate reflecting the estimated weighted average cost of capital of a market participant.

The revenue and margin assumptions were based on internal forecasts, which incorporate assumptions about future market conditions, product adoption rates, pricing, and competitive dynamics.

The discount rate utilized in the valuation of the Attune Medical asset group was 19.8 %, which reflects the higher risk profile, earlier stage of commercialization, and greater uncertainty in projected cash flows relative to the broader Interventional Technologies reporting unit.

The discount rate was developed using market-based inputs, including a risk-free rate, equity risk premium, and company-specific risk adjustments.

Cloud computing implementation costs

1 unchanged sentence

The Company includes these costs in other long-term assets.

The costs are amortized using the straight-line method over the

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

expected contract term, including extension periods and is included in selling, general and administrative expense in the Consolidated Statements of Income.

The costs are amortized using the straight-line method over the expected contract term, including extension periods and is included in selling, general and administrative expense in the consolidated statements of income.

Other long-term assets as of March 28, 2026 included approximately $ 62.4 million of capitalized implementation costs related to a new global enterprise resource planning system.

There were $ 44.0 million of implementation costs capitalized as of March 29, 2025.

Amortization expense was $ 2.3 million and $ 0.9 million in fiscal 2025 and 2024, respectively.

There was no amortization expense for fiscal 2023.

Amortization expense was $ 1.4 million, $ 1.4 million and $ 0.9 million in fiscal 2026, 2025 and 2024, respectively.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

5 unchanged sentences

There were no impairment charges recorded during fiscal 2026, 2025 and 2024.

In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded.

In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the marketplace, which could result in an impairment being recorded.

Refer to Note 10, Goodwill & Intangible Assets for more information regarding capitalized software.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Other Current Liabilities

1 unchanged sentence

The items included in the fiscal year end balances were:

(In thousands) March 29,

2025 March 30,

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Contract liabilities $ 42,310 $ 43,348

All other 104,785 104,846

Contingent consideration 17,597 2,278

Other 98,430 102,507

Total $ 158,337 $ 148,133

8 unchanged sentences

Shipping and handling costs are included in selling, general and administrative expenses.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The income tax provision is calculated for all jurisdictions in which the Company operates.

5 unchanged sentences

The Company records a liability for uncertain tax positions taken or expected to be taken in income tax returns.

The Company’s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts.

The Company’s consolidated financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts.

The Company records a liability for the portion of unrecognized tax benefits claimed that it has determined are not more-likely-than-not realizable.

4 unchanged sentences

The Company’s position is based upon several factors including management’s evaluation of Haemonetics’ and its subsidiaries’ financial requirements, the short-term and long-term operational and fiscal objectives of the Company and the tax consequences associated with the repatriation of earnings.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Convertible Senior Notes

The Company accounted for convertible senior notes as a single liability measured at its amortized cost.

The Company accounts for convertible senior notes as a single liability measured at its amortized cost.

At issuance, the carrying amount is calculated as the proceeds, net of initial debt issuance costs.

The difference between the principal amount and carrying value is amortized to interest expense over the term of the convertible senior notes using the effective interest rate method.

A detailed analysis of the terms of the convertible senior notes transactions is required to determine existence of any derivatives that may require separate mark-to-market accounting under applicable accounting guidance.

A detailed analysis of the terms of the convertible senior notes transactions is required to determine the existence of any derivatives that may require separate mark-to-market accounting under applicable accounting guidance.

Refer to Note 13, Financial Instruments and Fair Value Measurements for further details.

Derivative Instruments

The Company accounts for its derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) .

In accordance with ASC 815, the Company records all derivatives on the balance sheet at fair value.

The Company accounts for its derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging and ASC Topic 820, Fair Value Measurements and Disclosures.

In accordance with ASC Topic 815, the Company records all derivatives on the consolidated balance sheets at fair value.

The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative as a hedging instrument for accounting purposes and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting.

In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows.

In addition, ASC Topic 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows.

The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings.

4 unchanged sentences

These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies.

The Company recorded foreign currency gains of $ 0.9 million in fiscal 2025 , and foreign currency losses of $ 4.0 million and $ 1.0 million in fiscal 2024 and 2023, respectively.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company recorded foreign currency losses of $ 3.2 million in fiscal 2026, foreign currency gains of $ 0.9 million in fiscal 2025, and foreign currency losses of $ 4.0 million in fiscal 2024.

On a quarterly basis, the Company assesses whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item.

3 unchanged sentences

The Company’s derivative instruments do not subject its earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged.

The Company does not enter into derivative transactions for speculative purposes and it does not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC 815.

The Company does not enter into derivative transactions for speculative purposes and it does not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC Topic 815.

Refer to Note 13, Financial Instruments and Fair Value Measurements .

Share-Based Compensation

The Company expenses the fair value of share-based awards granted to employees, board members and others, net of estimated forfeitures.

To calculate the grant-date fair value of its stock options the Company uses the Black-Scholes option-pricing model and for performance share units it uses Monte Carlo simulation models.

To calculate the grant-date fair value of its stock options the Company uses the Black-Scholes option-pricing model, for performance share units based on relative total shareholder return (“rTSR”) the Company uses Monte Carlo simulation models, and for performance share units based on the average annual organic revenue growth rate (“AAGR”) the Company recognizes expense based on the number of awards expected to vest, which requires management to assess the probability of achieving the performance conditions.

This assessment is based on internal revenue forecasts, historical performance and current market conditions, and is reassessed at each reporting date.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Costs Associated with Exit Activities

4 unchanged sentences

Other costs associated with exit activities may include contract termination costs, including costs related to leased facilities to be abandoned or subleased, consultant fees and impairments of long-lived assets.

The costs are expensed in accordance with ASC Topic 420 and ASC Topic 360 , Property, Plant and Equipment and are included in costs of goods sold and selling, general and administrative costs in its consolidated statement of income.

Additionally, costs directly related to the Company’s active restructuring initiatives, including program management costs, accelerated depreciation and costs to transfer product lines among facilities are included within costs of goods sold and selling, general and administrative costs in its consolidated statement of income.

Refer to Note 5, Restructuring, for further information and discussion of its restructuring plans.

6 unchanged sentences

Strategic Investments

The Company holds strategic investments, including preferred stock and a special share, in privately held entities.

The special share allows the Company to acquire the related entity in accordance with an agreement between the parties.

As these equity instruments do not have readily determinable fair values, they have been measured using the measurement alternative, at cost less impairment.

The Company holds strategic investments in privately held entities.

Certain of these investments are accounted for under the equity method to the extent the Company determines it has the ability to exercise significant influence over the operating and financial policies of the investees.

For equity instruments that do not have readily determinable fair values and are not accounted for under the equity method, the Company applies the measurement alternative, recording them at cost less impairment.

The carrying amount for these instruments would be subsequently adjusted for observable price changes, or prices in orderly transactions for an identical investment or similar investment of the same issuer.

In addition, these investments are periodically evaluated for impairment.

The investments are classified as other long-term assets on the Company’s

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Consolidated Balance Sheets and the Company did not record any adjustments to the carrying value of strategic investments in fiscal 2025 or 2024.

In addition, these investments are periodically evaluated for impairment, and the investments are classified as other long-term assets on the Company’s consolidated balance sheets.

In cases where the Company acquires a company in which it previously held an equity stake, the Company attributes a portion of the purchase price to the previously-held equity interest, which is implied based on the total purchase consideration allocable to each of the shareholders, including Haemonetics, according to priority of equity interests.

The Company remeasures its previously held equity interest in the acquiree at its acquisition date fair value and records a gain or loss for the difference between the fair value and carrying value in interest and other expense, net in the consolidated statements of income.

Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for further information and discussion regarding the acquisition.

Concentration of Credit Risk and Significant Customers

1 unchanged sentence

In fiscal 2026, 2025 and 2024, the Company’s ten largest customers accounted for approximately 44 %, 42 % and 48 % of net revenues, respectively.

In fiscal 2025, no customer was greater than 10 % of total net revenues.

Four customers accounted for greater than 10 % of the Plasma segment’s net revenues and two customers accounted for greater than 10 % of the Blood Center segment’s net revenues, but did not exceed 10% of total net revenues, in fiscal 2025.

In fiscal 2026, one Plasma customer accounted for approximately 13 % of total net revenues.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Certain markets and industries can expose the Company to concentrations of credit risk.

7 unchanged sentences

If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Recent Accounting Pronouncements

Standards Implemented

In November 2023, the FASB issued ASC Update No.

2023-07, Segment Reporting (Topic 280).

The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker.

ASC Update No.

2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted.

The Company adopted the new guidance effective for this report for the fiscal year ended March 29, 2025, and has retrospectively included any additional disclosures in the previous periods included in this report.

Refer to Note 18 Segment and Enterprise-Wide Information for the new disclosures.

Standards to be Implemented

Recently Adopted Accounting Pronouncements

In December 2023, the FASB issued ASC Update No.

2023-09, Income Taxes (Topic 740):

Improvements to Income Tax Disclosures .

ASC Update No.

2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis.

The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted.

2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid.

ASC Update No.

2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.

2023-09 is effective for the Company’s first fiscal year beginning after December 15, 2024 and early adoption is permitted.

ASC Update No.

2023-09 became applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K.

The Company adopted the new guidance effective December 28, 2025 on a prospective basis .

Refer to Note 6, Income Taxes for further presentation on this.

In September 2025, the FASB issued ASC Update No.

2025-07, Derivatives and Hedging and Revenue from Contracts with Customers .

ASC Update No.

2025-07 reduces cost, complexity and diversity in practice of evaluating whether contracts with features based on the operations or activities of one of the parties to the contract are derivatives.

The updated guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted.

The Company elected to early adopt ASU Update No.

2025-07 on a prospective basis effective the beginning of the fourth quarter of fiscal 2026 .

The adoption did not have a material impact on the financial statements, including prior interim periods.

Recently Issued Accounting Pronouncements Not Yet Adopted

In November 2024, the FASB issued ASC Update No.

2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).

2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures .

ASC Update No.

2024-03 requires detailed cost and expense information disaggregated in the financial statement notes.

2024-03 requires detailed cost and expense information disaggregated in the financial statements notes.

The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted.

ASC Update No.

2024-03 is applicable to the Company beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

2024-03 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

In July 2025, the FASB issued ASC Update No.

2025-05, Financial Instruments - Credit Losses ( Topic 326 ).

ASC Update No.

2025-05 introduces a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under FASB Accounting Standards Codification 606.

Under ASC Update No.

2025-05, an entity is required to disclose whether it has elected to use the practical expedient.

An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated.

The updated guidance is effective for fiscal years beginning December 15, 2025, with early adoption permitted.

ASC Update No.

2025-05 is applicable to Haemonetics beginning with the fiscal 2027 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

The guidance can be applied on a prospective basis with the option to apply the standard retrospectively.

In September 2025, the FASB issued ASC Update No.

2025-06, Intangibles - Goodwill and Other - Internal-Use Software .

ASC Update No.

2025-06 eliminates references to development stages in the capitalization guidance and requires costs to be capitalized once management authorizes funding and will be completed and used as intended.

The updated guidance is effective for fiscal years beginning after December 15, 2027, with early adoption permitted.

ASC Update No.

2025-06 is applicable to Haemonetics beginning with the fiscal 2029 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

The guidance can be applied on a prospective basis with the option to apply the standard retrospectively.

In November 2025, the FASB issued ASC Update No.

2025-09, Derivatives and Hedging.

ASC Update No.

2025-09 enables groups of forecasted transactions to now share similar risk exposure with ongoing assessments of risk similarity to better reflect economic hedging strategies.

The updated guidance is effective for fiscal years beginning after December 15, 2028, with early adoption permitted.

ASC Update No.

2025-09 is applicable to Haemonetics beginning with the fiscal 2030 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

The guidance will be applied on a prospective basis with the option to apply the standard retrospectively.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In December 2025, the FASB issued ASC Update No.

2025-11, Interim Reporting.

ASC Update No.

2025-11 improves navigability and consistency in interim reporting by providing a comprehensive list of interim disclosures that are required from U.S.

GAAP as well as a disclosure principle for additional transparency.

The updated guidance is effective for fiscal years beginning after December 15, 2027, with early adoption permitted.

ASC Update No.

2025-11 is applicable to Haemonetics beginning with the fiscal 2029 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

In December 2025, the FASB issued ASC Update No.

2025-12, Codification Improvements.

ASC Update No.

2025-12 makes a broad set of technical corrections, clarifications and targeted improvements to the FASB Accounting Standards Codification to address unintended application issues and improve the operability of U.S.

GAAP across a range of topics.

The updated guidance is effective for fiscal years beginning after December 15, 2026, with early adoption permitted.

ASC Update No.

2025-12 is applicable to Haemonetics beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Vivasure Medical Limited

On January 9, 2026, the Company acquired all of the outstanding equity interests of Vivasure Medical Limited (“Vivasure”) for a net purchase price of $ 164.4 million.

The net purchase price included $ 60.2 million paid in cash at closing, net of $ 0.4 million cash acquired and after giving effect to the value of certain prior investments and loans made by the Company to Vivasure, as well as other customary closing adjustments, and the fair value of contingent consideration of $ 20.7 million.

The contingent consideration is based on sales growth over the three years following the completion of the acquisition and the achievement of certain other milestones, and is also subject to adjustments based on the value of certain prior investments and loans.

The Company financed this transaction through available cash on hand.

During fiscal 2026, the Company recorded a gain of $ 4.9 million within interest and other expense, net on the consolidated statements of income as a result of the remeasurement of the Company’s prior equity interest of approximately 30 % in Vivasure, which had a fair value of $ 47.3 million.

Vivasure is a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.

Vivasure’s PerQseal ® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures.

In 2025, Vivasure submitted a premarket approval application to the U.S.

FDA for the PerQseal Elite arterial closure system and received CE Mark in Europe for both arterial and venous indications.

The addition of Vivasure expands the Hospital business unit portfolio in the interventional cardiology market and will be included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date.

The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The assessment of fair value is preliminary and is based on information that was available at the time the Company’s consolidated financial statements were prepared.

Measurement period adjustments may arise upon the availability of further information regarding events or circumstances that existed at the acquisition date and will be recorded in the period in which they are determined, as if they had been completed at the acquisition date.

The finalization of the Company’s purchase accounting assessment could result in changes in the valuation of assets acquired and liabilities assumed, which could be material.

The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by Topic 805.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The total purchase price of $ 164.4 million consists of the amounts presented below, which represent the initial determination of the fair value of the identifiable assets acquired and liabilities assumed:

January 9, 2026

(Dollars in Thousands)

Cash and cash equivalents $ 449

Accounts receivable 21

Inventories 1,056

Prepaid expenses and other current assets 1,736

Property, plant and equipment 575

Intangible assets 117,100

Goodwill 50,478

Other long-term assets 1,972

Total assets acquired $ 173,387

Accounts payable $ 1,186

Accrued payroll and related costs 2,889

Other current liabilities 4,741

Other long-term liabilities 199

Total liabilities assumed 9,015

Net assets acquired $ 164,372

The Company determined that the identifiable intangible asset was primarily developed technology.

The fair value of the intangible asset was based on valuation techniques with estimates and assumptions developed by the Company.

Developed technology was valued using the excess earnings method.

In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible asset and assumed liabilities was recorded as goodwill.

As a result of the acquisition of Vivasure, the Company recognized goodwill of $ 50.5 million based on expected synergies from integration into the Company’s Hospital business unit.

The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:

Amount Weighted-Average Amortization Period Risk-Adjusted Discount

Rates used in Purchase Price Allocation

(Dollars in Thousands)

Developed technology $ 117,100 16 years 16.5 %

Total $ 117,100

Acquisition-Related Costs

The Company incurred $ 1.1 million of acquisition-related costs during fiscal 2026 in connection with the Vivasure acquisition.

These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the consolidated statements of income.

The Company’s consolidated financial statements include the results of Vivasure from the date the acquisition was completed.

Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

For information regarding the remeasurement of the contingent consideration liability refer to Note 13, Financial Instruments and Fair Value Measurements.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM ® proactive esophageal cooling device, pursuant to which among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical.

On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $ 187.7 million, which included an upfront cash payment of $ 162.0 million, or $ 150.5 million net of cash acquired, the fair value of contingent consideration of $ 25.3 million, and $ 0.4 million of working capital adjustments.

On March 5, 2024, the Company entered into a definitive agreement to acquire Attune Medical, the manufacturer of the ensoETM ® proactive esophageal cooling device, pursuant to which among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical.

On April 1, 2024, the Company completed its acquisition of Attune Medical for a net purchase price of $ 176.2 million, which included an upfront cash payment of $ 162.0 million, or $ 150.5 million net of $ 11.5 million cash acquired, the fair value of contingent consideration of $ 25.3 million, and $ 0.4 million of working capital adjustments.

The contingent consideration is based on sales growth over the next three years , which is uncapped, and the achievement of certain other milestones.

Refer to Note 13 Acquisitions, Divestitures and Strategic Investments for further information regarding the contingent consideration liability.

Refer to Note 13, Financial Instruments and Fair Value Measurements for further information regarding the contingent consideration liability.

The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

2 unchanged sentences

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date.

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC 805, Business Combinations , recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date.

The purchase price of $ 176.2 million , net of $ 11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) April 1, 2024

The purchase price of $ 176.2 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

April 1, 2024

(Dollars in Thousands)

Accounts receivable $ 3,784

11 unchanged sentences

Net assets acquired $ 176,206

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names.

6 unchanged sentences

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill.

As a result of the acquisition of Attune Medical, the Company recognized goodwill of $ 70.3 million based on expected synergies from integration into our Hospital business.

As a result of the acquisition of Attune Medical, the Company recognized goodwill of $ 70.3 million based on expected synergies from integration into the Company’s Hospital business unit.

The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Intangible assets acquired consist of the following:

(In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount

Amount Weighted-Average Amortization Period Risk-Adjusted Discount

Rates used in Purchase Price Allocation

(Dollars in Thousands)

Developed technology $ 96,100 10 years 22.0 %

8 unchanged sentences

Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

For information regarding the remeasurement of the contingent consideration liability refer to Note 13.

Financial Instruments and Fair Value Measurements .

For information regarding the remeasurement of the contingent consideration liability refer to Note 13, Financial Instruments and Fair Value Measurements .

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc.

(“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens.

On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $ 254.5 million, or $ 243.9 million, net of cash acquired.

On December 12, 2023, the Company completed its acquisition of OpSens for a net purchase price of $ 243.9 million, reflecting total consideration of $ 254.5 million, net of $ 10.6 million of cash acquired.

The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

1 unchanged sentence

OpSens’ core products include the SavvyWire ® , a sensor-guided 3-in-1 guidewire for transcatheter aortic valve replacement (“TAVR”) procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients;

and the OptoWire ® , a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (“FFR”) and diastolic pressure ratio (“dPR”) to aid clinicians in the diagnosis and treatment of patients with

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

coronary artery disease.

and the OptoWire ® , a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve and diastolic pressure ratio to aid clinicians in the diagnosis and treatment of patients with coronary artery disease.

OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.

1 unchanged sentence

Purchase Price Allocation

The purchase price of $ 243.9 million , net of $ 10.6 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

(In thousands) December 12, 2023

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The purchase price of $ 243.9 million consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:

December 12, 2023

(Dollars in Thousands)

Accounts receivable $ 5,960

20 unchanged sentences

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill.

As a result of the acquisition of OpSens, the Company recognized goodwill of $ 79.4 million based on expected synergies from integration into our Hospital business.

As a result of the acquisition of OpSens, the Company recognized goodwill of $ 79.4 million based on expected synergies from integration into the Company’s Hospital business unit.

The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Intangible assets acquired consist of the following:

(In thousands) Amount Weighted-Average Amortization Period Risk-Adjusted Discount

Amount Weighted-Average Amortization Period Risk-Adjusted Discount

Rates used in Purchase Price Allocation

(Dollars in Thousands)

Developed technology $ 114,900 15 years 20.5 %

8 unchanged sentences

Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Divestiture of the Whole Blood Product Line

3 unchanged sentences

The assets that were derecognized in connection with the sale consisted of $ 26.4 million of inventory, $ 7.8 million of property, plant and equipment and $ 6.4 million of goodwill, which were previously classified as held for sale in prepaid expenses and other current assets in the consolidated balance sheets in the third quarter of fiscal 2025.

In connection with the sale, the Company recognized a gain from the sale of the business in Interest and other expense, net in the Consolidated Statements of Income for the year ended March 29, 2025.

In connection with the sale, the Company recognized a gain from the sale of the business in i nterest and other expense, net in the consolidated statements of income for the year ended March 29, 2025.

The gain was not material and included the cash receipts of $ 43.3 million less net assets transferred to GVS or otherwise derecognized and net of transaction costs of $ 0.1 million .

As part of the sale, the Company entered into a Transition Services Agreement (“TSA”) with GVS to ensure a smooth transition of business operations.

Under the TSA, the Company will continue to provide certain regulatory, quality, logistical and operational support services to GVS for a maximum period of 36 months f ollowing the transaction closing to facilitate GVS's integration of the acquired business.

Under the TSA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the Consolidated Statements of Income, which were immaterial for fiscal 2025.

Under the TSA, the Company will continue to provide certain regulatory, quality, logistical and operational support services to GVS f or a maximum period of 36 months following the transaction closing to facilitate GVS's integration of the acquired business.

Under the TSA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the consolidated statements of income, which was approximately $ 0.4 million during fiscal 2026.

In addition to the TSA, Haemonetics and GVS entered into a Contract Manufacturing Agreement (“CMA”), under which Haemonetics will continue to manufacture certain whole blood filtration products for GVS for a maximum term of 18 months.

The CMA allows GVS to gradually transition manufacturing operations while ensuring supply continuity for customers.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

the CMA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the Consolidated Statements of Income, which were immaterial for fiscal 2025.

Under the CMA, the Company is entitled to be reim bursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the consolidated statements of income, which was approximately $ 1.7 million during fiscal 2026.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities.

During fiscal years 2025 , 2024 and 2023, the Company made investments in Vivasure Medical LTD (“Vivasure”), totaling € 9.5 million, € 5.0 million and € 30.0 million, respectively.

The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties.

In addition, the Compan y has made certain other strategic investments totalin g $ 7.0 million and $ 7.6 million during fiscal years 2025 and 2024.

The Company’s strategic investments are classified as other long-term assets on the consolidated balance sheets and the Company did not record any adjustments to the carrying value of our strategic investments in fiscal 2025, fiscal 2024 or fiscal 2023.

The Company has strategic investments totaling $ 19.2 million as of March 28, 2026.

As of March 29, 2025, the Company had strategic investments and loans of $ 61.6 million, including $ 48.7 million in strategic investments and loans to Vivasure.

On January 9, 2026 the Company completed the acquisition of Vivasure.

The Company’s strategic investments are classified as other long-term assets on the Company’s consolidated balance sheets, and the Company has not recorded any material adjustments to the carrying value of the Company’s strategic investments, other than those related to the Vivasure acquisition, in fiscal 2026, fiscal 2025 or fiscal 2024.

As of March 28, 2026, the Company had $ 35.9 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more.

3 unchanged sentences

The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

As of March 28, 2026 and March 29, 2025, the Company had contract liabilities of $ 42.3 million and $ 43.3 million, respectively.

During fiscal 2025 , we recognized $ 29.1 million of revenue that was included in the above March 30, 2024 contract liability balance.

Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheet.

During fiscal 2026, the Company recognized $ 5.4 million of revenue that was included in the above March 29, 2025 contract liability balance.

Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheets.

As of March 28, 2026 and March 29, 2025, the Company’s contract assets were $ 5.5 million and $ 11.6 million, respectively.

5 unchanged sentences

During fiscal 2022, the Company revised the 2020 Program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic.

The program is closed as of March 29, 2025.

During fiscal 2025 , 2024 and 2023, the Company incurred $ 7.7 million, $ 9.8 million and $ 11.5 million of restructuring and restructuring related costs under this program, respectively.

Total cumulative charges under this program are $ 84.7 million as of March 29, 2025.

The 2020 Program closed as of March 29, 2025.

During fiscal 2025 and 2024, the Company incurred $ 7.7 million and $ 9.8 million of restructuring and restructuring related costs under this program, respectively.

Total cumulative charges under the 2020 Program were $ 84.7 million through March 29, 2025.

Portfolio Rationalization Initiatives

In November 2023, the C ompany announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities.

The initiative is closed as of March 29, 2025 .

During fiscal 2025 , 2024 and 2023, the Company incurred $ 13.0 million, $ 14.0 million and no restructuring and restructuring related costs under this initiative, respectively.

Total cumulative charges under this initiative are $ 27.0 million as of March 29, 2025.

These portfolio rationalization initiatives closed as of March 29, 2025 .

Under these initiatives, during fiscal 2026 the Company recognized reversals of previously incurred costs of $ 1.9 million, as compared with restructuring and restructuring related costs incurred of $ 13.0 million and $ 14.0 million, respectively, during fiscal 2025 and fiscal 2024.

Total cumulative charges under these portfolio rationalization initiatives are $ 25.1 million as of March 28, 2026.

Market and Regional Alignment Initiative

In May 2025, the Board approved the currently ongoing market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative.

This strategic initiative is designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities.

Initial actions related to this initiative were approved by the Board in January 2025, resulting in restructuring related costs during the fourth quarter of fiscal 2025.

Under this initiative, during fiscal 2026 and 2025, the Company incurred restructuring and restructuring related costs of $ 5.1 million and $ 0.6 million, respectively, under this initiative.

Total cumulative charges under the market and regional alignment initiative are $ 5.6 million as of March 28, 2026.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Market and Regional Alignment

In May 2025, the Board of Directors of the Company approved a new market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative.

We expect to incur aggregate restructuring and restructuring-related charges of approximately $ 20 million associated with this initiative, approximately half of which we expect will consist of severance and other employee costs and the remainder of which will consist of other exit costs, primarily related to third party arrangements.

These charges, substantially all of which will result in cash outlays, will be incurred as the specific actions required to execute on the initiative are identified and approved and are expected to continue through the end of fiscal 2027.

We expect savings from this initiative of approximately $ 30 million on an annua lized basis once the initiative is completed.

The amounts and timing of estimated costs and savings are subject to change until finalized.

The actual amounts and timing may vary materially based on various factors.

During the fourth quarter of fiscal 2025 , the Company incurred $ 0.6 million of restructuring related costs related to the first action under this initiative, which were approved by our Board of Directors in January 2025.

Total cumulative charges under this program are $ 0.6 million as of March 29, 2025.

The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives, 2020 Program and market and regional alignment initiative for the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees:

(In thousands) Portfolio Rationalization 2020 Program Market and Regional Alignment Prior Programs Total

Balance at April 2, 2022

$ — $ 2,460 $ — $ 345 $ 2,805

The following table summarizes the activity for restructuring reserves related to prior programs, the 2020 Program, portfolio rationalization initiatives, and market and regional alignment initiatives for the fiscal years 2026, 2025 and 2024, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees:

Prior Programs 2020 Program Portfolio Rationalization Initiatives Market and Regional Alignment Initiatives Total

(Dollars in Thousands)

Balance as of April 1, 2023 $ 340 $ 1,810 $ — $ — $ 2,150

Costs incurred, net of reversals ( 276 ) 450 13,915 — 14,089

Payments ( 64 ) ( 1,775 ) ( 2,606 ) — ( 4,445 )

Balance at April 1, 2023 $ — $ 1,810 $ — $ 340 $ 2,150

Balance as of March 30, 2024 $ — $ 485 $ 11,309 $ — $ 11,794

Costs incurred, net of reversals — 566 12,797 550 13,913

Payments — ( 761 ) ( 12,755 ) ( 550 ) ( 14,066 )

Balance at March 30, 2024 $ 11,309 $ 485 $ — $ — $ 11,794

Non-cash adjustments — — ( 8,616 ) — ( 8,616 )

Balance as of March 29, 2025 $ — $ 290 $ 2,735 $ — $ 3,025

Costs incurred, net of reversals — ( 62 ) ( 1,919 ) 5,095 3,114

Payments — ( 205 ) ( 100 ) ( 4,527 ) ( 4,832 )

Non-cash adjustments ( 8,616 ) — — — ( 8,616 )

Balance at March 29, 2025 $ 2,735 $ 290 $ — $ — $ 3,025

The following presents the restructuring costs by line item during fiscal 2025 , 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:

(In thousands) 2025 2024 2023

Balance as of March 28, 2026 $ — $ 23 $ 716 $ 568 $ 1,307

The following presents the restructuring costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income:

2026 2025 2024

(Dollars in Thousands)

Cost of goods sold $ ( 496 ) $ 11,328 $ 11,286

3 unchanged sentences

As of March 28, 2026, the Company had a restructuring liability of $ 1.3 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $ 7.2 million, $ 9.5 million and $ 10.9 million in fiscal 2025, 2024 and 2023, respectively, that do not constitute restructuring costs under ASC 420,

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $ 0.1 million, $ 7.2 million and $ 9.5 million in fiscal 2026, 2025 and 2024, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs.

These costs consist primarily of expenditures directly related to the restructuring actions.

The following presents the restructuring related costs by line item during fiscal 2025 , 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:

(In thousands) 2025 2024 2023

The following presents the restructuring related costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income:

2026 2025 2024

(Dollars in Thousands)

Cost of goods sold $ ( 33 ) $ 3,304 $ 5,734

2 unchanged sentences

Total $ 105 $ 7,245 $ 9,499

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The tables below present restructuring and restructuring related costs by reportable segment:

2026 2025 2024

(Dollars in Thousands)

Restructuring costs

(In thousands) 2025 2024 2023

Plasma $ 447 $ 258 $ 1,015

4 unchanged sentences

Restructuring related costs

(In thousands) 2025 2024 2023

Plasma $ 9 $ 281 $ 1,050

4 unchanged sentences

Total restructuring and restructuring related costs $ 3,219 $ 21,158 $ 23,588

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Domestic and foreign income before provision for income tax is as follows:

(In thousands) 2025 2024 2023

2026 2025 2024

(Dollars in Thousands)

Domestic $ 87,236 $ 161,800 $ 112,563

2 unchanged sentences

The income tax provision (benefit) from continuing operations contains the following components:

(In thousands) 2025 2024 2023

2026 2025 2024

(Dollars in Thousands)

Federal $ 35,794 $ 29,818 $ 29,113

7 unchanged sentences

Total $ 30,722 $ 44,392 $ 34,307

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States.

2 unchanged sentences

The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs, and is favorably impacted by changes in contingent consideration revaluation, the expiration of the statute of limitations with respect to certain uncertain tax position reserves, jurisdictional mix of earnings, impact of foreign tax law changes and research credits generated.

The Company’s subsidiary in Malaysia has been granted a full income tax exemption on manufacturing income that could be in effect for up to ten years , provided certain conditions are satisfied.

The income tax exemption was in effect beginning June 1, 2016.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Tax effected, significant temporary differences comprising the net deferred tax liability are as follows:

(In thousands) March 29,

2026 March 29,

(Dollars in Thousands)

Deferred tax assets:

19 unchanged sentences

Net deferred tax liabilities $ ( 28,527 ) $ ( 54,772 )

The valuation allowance increase of $ 1.7 million during fiscal 2025 is primarily due to an increase in the valuation allowance against foreign deferred tax assets and other income tax attributes generated during the fiscal year that are expected to expire unutilized .

The valuation allowance increase of $ 2.3 million during fiscal 2026 is primarily due to an increase in valuation allowances established against acquired attributes offset by a decrease in the valuation allowance against foreign deferred tax assets and other income tax attributes utilized during the fiscal year .

The Company has assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income.

It has also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets.

The Company has concluded future taxable income can be considered a source of income to realize a benefit for deferred tax assets in certain jurisdictions.

The Company has concluded that future taxable income can be considered a source of income to realize a benefit for deferred tax assets in certain jurisdictions.

The Company believes it is able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence.

3 unchanged sentences

state net operating loss and tax credit carryforwards that are not more-likely-than-not realizable, as well as a valuation allowance against the deferred tax assets of certain foreign subsidiaries.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In connection with certain acquisitions, the Company has acquired net operating loss and tax credit carryforwards, which may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent as defined under Section 382 and 383 of the U.S.

4 unchanged sentences

The remaining carryforwards disclosed in the deferred tax table above represent the amount of attributes that can be utilized based on the results of the studies.

The Company does not believe it has had any additional ownership change that would result in additional limitation.

The Company does not believe it has had any additional ownership change that would result in additional limitations.

Subsequent ownership changes may further affect the limitation in future years.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In fiscal 2026, the Company acquired approximately $ 135.5 million of net operating losses in Ireland as a result of the acquisition of Vivasure.

The Company has preliminarily concluded that the transaction does not result in the net operating losses being subject to any utilization limitations associated with the acquisition itself.

As of March 28, 2026, the Company has U.S.

2 unchanged sentences

state net operating losses of $ 51.5 million of which $ 51.0 million will expire at various times between fiscal 2027 and fiscal 2044 and $ 0.5 million can be carried forward indefinitely.

The Company has federal and state tax credits of $ 0.5 million and $ 6.2 million, respectively, which will begin to expire in fiscal 2030 and fiscal 2026, respectively.

The Company has federal tax credits of $ 0.6 million that will begin to expire in fiscal 2030 and state tax credits of $ 6.6 million that began to expire in fiscal 2029.

As of March 28, 2026, the Company has Canadian federal and provincial net operating loss carryforwards of $ 21.5 million and $ 18.2 million, respectively, which will expire from fiscal 2036 through fiscal 2045.

Additionally, the Company has Irish net operating loss carryforwards of $ 140.0 million that can be carried forward indefinitely.

The Company has other foreign net operating losses of approximately $ 6.8 million that are available to reduce future income which can be carried forward indefinitely.

1 unchanged sentence

As of March 28, 2026, substantially all of the unremitted earnings of the Company have been taxed in the U.S.

The Company has not provided U.S.

deferred income taxes or foreign withholding taxes on unremitted earnings of foreign subsidiaries of approximately $ 90.8 million as such amounts are considered to be indefinitely reinvested in the business.

The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as its subsidiaries continue to expand their operations and to fund future foreign acquisitions.

The Company does not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations, however a significant portion of the unremitted earnings could be remitted without a future tax cost.

The income tax provision differs from the tax provision computed at the U.S.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In accordance with the adoption of ASC Update No.

2023-09, income tax provision differs from the tax provision computed at the U.S.

federal statutory income tax rate due to the following:

(In thousands) 2025 2024 2023

Year Ended March 28, 2026

(Dollars in Thousands)

Tax at federal statutory rate $ 26,886 21.0 %

State income taxes net of federal benefit (1)

Foreign tax effects

Statutory tax rate difference ( 5,051 ) ( 3.9 ) %

Local income tax 2,246 1.8 %

Other items 21 — %

Local income tax ( 1,838 ) ( 1.5 ) %

Other items ( 1,071 ) ( 0.8 ) %

Ireland 1,341 1.0 %

Other foreign jurisdictions 3,267 2.6 %

Effect of cross-border tax laws ( 770 ) ( 0.6 ) %

Nontaxable or nondeductible items

Other nontaxable or nondeductible items 1,496 1.2 %

Limitation on executive compensation 3,434 2.7 %

Federal research credits ( 3,089 ) ( 2.4 ) %

Other tax credits ( 852 ) ( 0.7 ) %

Changes in valuation allowances 37 — %

Changes in unrecognized tax benefits 54 — %

Other, net 1 — %

Income tax provision $ 30,722 24.0 %

(1) The jurisdictions which account for the majority of the tax effect in this category include California, Texas, Florida, New York, Pennsylvania, Illinois and Georgia.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Prior to the adoption of ASC Update No.

2023-09, income tax provision differed from the tax provision computed at the U.S.

federal statutory income tax rate due to the following:

(Dollars in Thousands)

Tax at federal statutory rate $ 44,535 21.0 % $ 31,892 21.0 %

Impact of foreign operations ( 732 ) ( 0.3 ) % ( 3,631 ) ( 2.4 ) %

6 unchanged sentences

Non-deductible expenses 2,845 1.3 % 2,355 1.6 %

Stock compensation shortfalls (benefits) ( 4,469 ) ( 2.1 ) % ( 1,841 ) ( 1.2 ) % 1,883 1.3 %

Stock compensation benefits ( 4,469 ) ( 2.1 ) % ( 1,841 ) ( 1.2 ) %

Research credits ( 2,411 ) ( 1.1 ) % ( 1,378 ) ( 0.9 ) %

4 unchanged sentences

Income tax provision $ 44,392 20.9 % $ 34,307 22.6 %

The Company recorded an income tax expense of $ 44.4 million, representing an effective tax rate of 20.9 %.

The effective tax rate is unfavorably impacted by state taxes, non-deductible executive compensation and disallowed stock compensation and transaction expenses, offset by the favorable impact of changes in contingent consideration revaluation, the expiration of the statute of limitations with respect to certain uncertain tax position reserves, jurisdictional mix of earnings, impact of foreign tax law changes and research credits generated.

The 15% global minimum tax under the Organization for Economic Cooperation and Development’s (“OECD”) Pillar Two Global Anti-Base Erosion Rule is currently effective in certain jurisdictions in which we operate.

The Company recorded an income tax expense in fiscal 2026 of $ 30.7 million, representing an effective tax rate of 24.0%.

The effective tax rate is unfavorably impacted by state taxes and non-deductible executive compensation, offset by the favorable impact of changes in jurisdictional mix of earnings and research credits generated.

The OECD continues to issue guidance on the Pillar Two framework and various countries continue to enact legislation with respect to their application of the framework.

We have considered the Pillar Two rules in effect in the countries in which we operate and have reflected the effect of the rules in the impact of foreign operations.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company has considered the Pillar Two rules in effect in the countries in which it operates and have reflected the effect of the rules in the foreign tax effects.

The impact is not material in fiscal 2026.

Unrecognized Tax Benefits

2 unchanged sentences

As of March 29, 2025, the Company had $ 2.8 million of unrecognized tax benefits, of which $ 1.8 million would impact the effective tax rate, if recognized.

As of April 1, 2023, the Company had $ 3.9 million of unrecognized tax benefits, of which $ 3.2 million would impact the effective tax rate, if recognized.

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023:

(In thousands) March 29,

As of March 30, 2024, the Company had $ 3.7 million of unrecognized tax benefits, of which $ 3.1 million would impact the effective tax rate, if recognized.

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 28, 2026, March 29, 2025 and March 30, 2024:

2026 March 29,

2024 April 1,

2025 March 30,

(Dollars in Thousands)

Beginning Balance $ 2,822 $ 3,743 $ 3,941

Additions for tax positions of the current year 315 234 292

Additions for tax positions of a prior year 1,242 — —

Additions for tax positions of fiscal 2026 140 315 234

Additions for tax positions of a prior fiscal year 9 1,242 —

Additions for tax positions related to acquired businesses — 91 —

Reductions of tax positions ( 111 ) ( 64 ) ( 198 )

Settlements of tax positions ( 1,242 ) — —

Expiration of statute of limitations ( 24 ) ( 2,505 ) ( 234 )

Ending Balance $ 1,594 $ 2,822 $ 3,743

As of March 29, 2025, the Company anticipates that the liability for unrecognized tax benefits for uncertain tax positions could change by an insignificant amount in the next twelve months.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company’s historical practice has been and continues to be to recognize interest and penalties related to federal, state and foreign income tax matters in income tax expense.

Approximately $ 0.1 million and $ 0.3 million of gross interest and penalties were accrued at March 29, 2025 and March 30, 2024, respectively, and are not included in the amounts above.

Additionally, a benefit of $ 0.3 million, an expense of $ 0.1 million, and an expense of $ 0.1 million of accrued interest and penalties were included in the income tax provision for each of the years ended March 29, 2025, March 30, 2024 and April 1, 2023, respectively.

Approximately $ 0.1 million of gross interest and penalties was accrued as of March 28, 2026 and March 29, 2025, respectively, and are not included in the amounts above.

Additionally, an expense of $ 0.1 million, a benefit of $ 0.3 million, and an expense of $ 0.1 million of accrued interest and penalties were included in the income tax provision for each of the years ended March 28, 2026, March 29, 2025 and March 30, 2024, respectively.

The Company conducts business globally and, as a result, files federal, state and foreign income tax returns in multiple jurisdictions.

3 unchanged sentences

To the extent that the Company has tax attribute carry-forwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state, or foreign tax authorities to the extent utilized in a future period.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following is a summary of cash income taxes paid, net of refunds:

(Dollars in Thousands)

Federal $ 41,750

Foreign 8,833

Total $ 60,665

EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.

(In thousands, except per share amounts) 2025 2024 2023

Net income $ 167,679 $ 117,558 $ 115,401

Weighted average shares 50,330 50,706 50,783

Basic income per share $ 3.33 $ 2.32 $ 2.27

2026 2025 2024

(Dollars and Shares in Thousands, Except Per Share Data)

Net income $ 97,308 $ 167,679 $ 117,558

Basic weighted average shares 50,330 50,706 50,783

Net effect of common stock equivalents 400 691 637

Basic weighted average shares outstanding 47,179 50,330 50,706

Dilutive net effect of common stock equivalents 175 400 691

Diluted weighted average shares 47,354 50,730 51,397

Diluted income per share $ 3.31 $ 2.29 $ 2.24

Net income per share

Basic $ 2.06 $ 3.33 $ 2.32

Diluted $ 2.05 $ 3.31 $ 2.29

Anti-dilutive shares excluded from the calculation 936 768 606

Basic earnings per share is calculated using the Company’s weighted average outstanding common shares.

1 unchanged sentence

From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of both the convertible senior notes.

For fiscal 2025, 2024 and 2023, weighted average shares outstanding, assuming dilution, excludes the impact of 0.8 million, 0.6 million and 0.6 million anti-dilutive shares, respectively.

2022 Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $ 300.0 million of Haemonetics common stock (the “Share Repurchase Authorization”), based on market conditions, through August 2025.

Under the Share Repurchase Authorization, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants.

The Share Repurchase Authorization may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

Under the 2022 share repurchase program, the Company was authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In fiscal 2023, the Company completed a $ 75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A.

3 unchanged sentences

The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $ 74.36 .

In February 2025, the Company entered into an ASR with Goldman Sachs & Co.

(“Goldman Sachs”) to repurchase $ 150.0 million of the Company’s common stock.

Pursuant to the ASR, in February 2025, the Company paid Citibank $ 150.0 million and received an additional delivery of 2.0 million shares of the Company’s common stock based on a closing market price on the New York Stock Exchange on February 7, 2025 of $ 59.34 , which represented 80 % of the total contract.

The ASR was completed in April 2025, subsequent to the end of the fourth quarter of fiscal 2025, and 0.4 million additional shares were delivered upon settlement.

As of March 29, 2025, we have fully funded the $300.0 million Share Repurchase Authorization.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Share Repurchase Authorization

In April 2025 the Company’s Board of Directors approved a new share repurchase authorization of up to $ 500 million of Haemonetics common stock over the next three years .

This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants.

In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans.

In April 2025, the Company completed a $ 150.0 million repurchase of its common stock pursuant to an ASR entered into with Goldman Sachs & Co.

(“Goldman Sachs”) in February 2025.

The total number of shares repurchased under the ASR was 2,386,131 at an average price per share upon final settlement of $ 62.86 .

As of March 29, 2025, the Company had fully funded the $ 300.0 million authorization under the 2022 share repurchase program.

2025 Share Repurchase Program

In April 2025 the Company’s Board of Directors approved a new share repurchase authorization of up to $ 500 million of Haemonetics common stock, based on market conditions, through April 2028.

Under the 2025 share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.

1 unchanged sentence

The 2025 share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In September 2025, the Company completed a $ 75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2025.

The total number of shares repurchased under the ASR was 1,430,579 at an average price per share upon final settlement of $ 52.43 .

During the fourth quarter of fiscal 2026, the Company repurchased $ 25.0 million of its common stock pursuant to a previously executed Rule 10b5-1 trading plan.

The total number of shares repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon final settlement of $ 69.36 .

In March 2026, the Company completed a $ 75.0 million repurchase of its common stock pursuant to an ASR entered into with Goldman Sachs in February 2026.

The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $ 61.54 .

As of March 28, 2026, the total remaining authorization for repurchases of the Company’s common stock under the 2025 share repurchase program was $ 325.0 million.

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead.

Cost is determined with the first-in, first-out method.

(In thousands) March 29, 2025 March 30, 2024

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Raw materials $ 114,873 $ 128,574

1 unchanged sentence

Finished goods 179,523 221,611

Total inventories $ 365,141 $ 317,202

Total $ 306,370 $ 365,141

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold .

The inventory related to the divestiture had a value of $ 26.4 million and h as been removed from the consolidated balance sheets .

In fiscal 2024, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S.

In fiscal 2024, the Company issued a voluntary recall of certain products within the Whole Blood portion of the Company’s Blood Center business unit sold to customers in the U.S.

and certain foreign jurisdictions.

The Company has recorded charges of $ 4.4 million related to inventory.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

(In thousands) March 29, 2025 March 30, 2024

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Land $ 2,251 $ 1,985

4 unchanged sentences

Construction in progress 29,943 22,229

Total 837,194 959,177

Property, plant and equipment, at cost 841,829 837,194

accumulated depreciation ( 536,068 ) ( 553,142 )

1 unchanged sentence

Depreciation expense was $ 61.2 million, $ 60.0 million and $ 55.8 million in fiscal 2026, 2025 and 2024, respectively.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold .

1 unchanged sentence

In the first quarter of fiscal 2025, the Company received $ 19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $ 14.1 million that was recorded in selling, general and administrative expenses on the consolidated statements of income.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by operating segment for fiscal 2026 and 2025 are as follows:

(In thousands) Plasma Blood Center Hospital Total

Carrying amount as of April 1, 2023 $ 29,043 $ 33,855 $ 403,333 $ 466,231

Plasma Blood Center Hospital Total

(Dollars in Thousands)

Carrying amount as of March 30, 2024 $ 29,043 $ 33,484 $ 502,555 $ 565,082

Divestitures — ( 6,381 ) — ( 6,381 )

Acquisitions — — 69,542 69,542

2 unchanged sentences

Carrying amount as of March 29, 2025 29,043 26,967 548,259 604,269

Divestitures — ( 6,381 ) — ( 6,381 )

Acquisitions — — 50,478 50,478

Purchase accounting adjustments — — ( 19,248 ) ( 19,248 )

Currency translation — ( 79 ) 1,700 1,621

Carrying amount as of March 28, 2026 $ 29,043 $ 26,888 $ 600,437 $ 656,368

The decrease in goodwill of $ 19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens.

The decrease in goodwill of $ 19.2 million for purchase accounting adjustments in fiscal 2025 was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens.

This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date.

Refer to Note 3 , Acquisitions, Divestitures and Strategic Investments , for additional information regarding the acquisitions of OpSens and Attune Medical.

Refer to Note 3 , Acquisitions, Divestitures and Strategic Investments , for additional information regarding the acquisitions of OpSens, Attune Medical and Vivasure.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold.

1 unchanged sentence

Refer to Note 3 , Acquisitions, Divestitures and Strategic Investments , for additional information regarding the divestiture of its Whole Blood product line.

The results of the Company’s goodwill impairment test performed in the fourth quarter of fiscal 2025, 2024 and 2023 indicated that the estimated fair value of all reporting units exceeded their respective carrying values.

Th ere were no reporting units at risk of impairment as of the fiscal 2025 , 2024 and 2023 annual test dates.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In fiscal 2026, 2025 and 2024, the results of the annual goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values, however, in fiscal 2026 the fair value of the Interventional Technologies reporting unit, which is within the Hospital reportable segment, fair value was $ 867.8 million, which only exceeded its carrying value of $ 821.6 million by 6 %.

The estimation of fair value requires significant judgment and is based primarily on a discounted cash flow approach, supplemented by market-based methods where appropriate.

Key assumptions include projected revenue growth rates, operating margins, terminal growth rates, and the discount rate.

These inputs are based on management’s expectations of future performance and market conditions and are inherently uncertain.

The Interventional Technologies reporting unit remains sensitive to changes in key assumptions.

A decline in projected revenue growth rates, or an increase in the discount rate, could result in the carrying value exceeding fair value.

The Company monitors for goodwill impairment indicators throughout the year, including changes in macroeconomic conditions, industry trends, and business performance.

No interim goodwill impairment indicators were identified during fiscal 2026 that required an additional recoverability test.

Although no goodwill impairment was recorded during fiscal 2026, the Interventional Technologies reporting unit remains at risk of future impairment if actual results differ from current estimates or if market conditions deteriorate.

The gross carrying amount of intangible assets and the related accumulated amortization as of March 28, 2026 and March 29, 2025 is as follows:

(In thousands) Gross Carrying

Gross Carrying

Amount Accumulated

Amortization Net

As of March 29, 2025

Amortization Net Carrying Amount Weighted Average Remaining Life (Years)

March 28, 2026 (Dollars in Thousands)

Developed technology $ 556,631 $ 193,114 $ 363,517 11.6

7 unchanged sentences

Total $ 5,903

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(In thousands) Gross Carrying

Gross Carrying

Amount Accumulated

Amortization Net

As of March 30, 2024

Amortization Net Carrying Amount Weighted Average Remaining Life (Years)

March 29, 2025 (Dollars in Thousands)

Developed technology $ 506,144 $ 156,123 $ 350,021 12.1

5 unchanged sentences

Non-amortizable:

In-process research and development $ 13,667

In-process software development 9,190

Total $ 9,190

During fiscal 2025, the Company acquired Attune Medical and recorded $ 96.1 million of developed technology, $ 7.8 million of customer contracts and related relationships and $ 1.9 million of trade name intangibles based on the purchase accounting valuation.

Refer to Note 3 Acquisitions, Divestitures and Strategic Investments , for additional information regarding the acquisition.

In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization.

In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $ 10.4 million related to the intangibles acquired as part of the e nicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $ 10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

During fiscal 2026, the Company recorded total intangible asset impairment charges of $ 86.5 million.

This included a $ 9.3 million intangible impairment charge in the first half of fiscal 2026 related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the Hospital business unit, as acquired from HemoAssay Science and Technology (Suzhou) Co.

Ltd., a China-incorporated company, and its affiliates (collectively, “HemoAssay”) in fiscal 2021.

The intangible impairment charge was the result of lower revenue projections of the HemoAssay devices and disposables.

The fair value as of March 28, 2026 was $ 0.8 million with a remaining useful life of approximately five years .

Additionally, in the fourth quarter of fiscal 2026, the Company recorded an intangible asset impairment charge of $ 77.2 million related to long-lived intangible assets associated with the acquisition of Attune Medical, which occurred in fiscal 2025 within the Interventional Technologies reporting unit, which is within the Hospital reportable segment.

The intangible impairment charge was the result of lower revenue projections, changes in market conditions and declines in operating performance.

The fair value as of March 28, 2026 was $ 11.3 million.

Significant unobservable inputs used in the Level 3 fair value measurement of the HemoAssay intangible assets included projected revenues, costs and the remaining useful lives of the assets.

The Level 3 inputs for the Attune Medical included projected revenues, operating margins, and a discount rate reflecting the estimated weighted average cost of capital of a market participant.

The revenue and margin assumptions were based on internal forecasts, which incorporate assumptions about future market conditions, product adoption rates, pricing, and competitive dynamics.

The discount rate was developed using market-based inputs, including a risk-free rate, equity risk premium, and company-specific risk adjustments.

The Company continues to monitor the HemoAssay and Attune Medical asset group for intangible impairment indicators, including macroeconomic conditions, industry trends, and changes in business performance.

While the intangible impairment charge recognized reflects management’s best estimate of fair value as of the testing date, it is reasonably possible that changes in assumptions or future business conditions could result in additional impairment charges in future periods.

In the fourth quarter of fiscal 2026, the Company acquired Vivasure and recorded $ 117.1 million of developed technology based on the purchase accounting valuation.

Refer to Note 3, Acquisitions, Divestitures and Strategic Investments , for additional information regarding the Vivasure acquisition.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold.

2 unchanged sentences

Refer to Note 3, Acquisitions, Divestitures and Strategic Investments , for additional information regarding the divestiture.

In fiscal 2024, the Company acquired OpSens and recorded $ 114.9 million of developed technology, $ 52.3 million of customer contracts and related relationships and $ 4.8 million of trade names.

Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

Intangible assets include the value assigned to license rights and developed technology, patents, customer contracts and relationships and trade names.

2 unchanged sentences

Amortization expense on intangible assets for the next five years is estimated to be as follows:

(In thousands)

Amortization Expense

(Dollars in Thousands)

Fiscal 2027 $ 46,864

3 unchanged sentences

Fiscal 2031 $ 40,359

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed , which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product.

Once technological feasibility is established, all software costs should be

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

capitalized until the product is available for general release to customers.

Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers.

The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

The Company capitalized $ 6.7 million and $ 7.7 million in software development costs for ongoing initiatives during fiscal 2026 and 2025, respectively.

At March 29, 2025 and March 30, 2024, the Company had a total of $ 94.7 million and $ 89.4 million of software costs capitalized, of which $ 9.2 million and $ 4.6 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives.

As of March 28, 2026 and March 29, 2025, the Company had a total of $ 101.8 million and $ 94.7 million, respectively, of software costs capitalized, of which $ 5.9 million and $ 9.2 million, respectively, are related to in process software development initiatives and the remaining balance represents in-service assets that are being amortized over their useful lives.

Amortization expense for capitalized software was $ 6.1 million, $ 6.7 million and $ 8.6 million for fiscal 2026, 2025 and 2024, respectively.

1 unchanged sentence

The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment.

Finance leases are not significant.

Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term.

Leases with an initial term of 12 months or less are not recognized on the consolidated balance sheets and expense for these leases is recognized on a straight-line basis over the lease term.

The Company accounts for the lease components and the non-lease components as a single lease component.

7 unchanged sentences

Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to the Company’s operating leases:

(In thousands) March 29, 2025 March 30, 2024

Operating lease right-of-use assets in Other long-term assets

$ 47,492 $ 55,268

Operating lease liabilities in Other current liabilities

$ 8,107 $ 8,133

Operating lease liabilities in Other long-term liabilities

$ 50,454 $ 57,958

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:

The following table presents supplemental consolidated balance sheets information related to the Company’s operating leases:

Classification March 28, 2026 March 29, 2025

(Dollars in Thousands)

Operating lease right-of-use assets Other long-term assets $ 39,619 $ 47,492

Operating lease liabilities Other current liabilities $ 9,243 $ 8,107

Operating lease liabilities Other long-term liabilities $ 40,898 $ 50,454

The following table presents the weighted average remaining lease term and discount rate information related to the Company’s operating leases:

March 28, 2026 March 29, 2025

Weighted average remaining lease term 7.5 years 8.2 years

Weighted average remaining lease term (years) 6.7 7.5

Weighted average discount rate 4.6 % 5.0 %

2 unchanged sentences

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table presents supplemental cash flow information related to our operating leases:

(In thousands) March 29, 2025 March 30, 2024 April 1, 2023

The following table presents supplemental cash flow information related to the Company’s operating leases:

March 28, 2026 March 29, 2025 March 30, 2024

(Dollars in Thousands)

Cash paid for amounts included in the measurement of operating lease liabilities

1 unchanged sentence

Right-of-use assets obtained in exchange for new operating lease liabilities $ 997 $ 399 $ 2,450

The following table presents the maturities of our operating lease liabilities as of March 29, 2025:

Fiscal Year ( In thousands )

The following table presents the maturities of the Company’s operating lease liabilities as of March 28, 2026:

Operating Leases

2026 $ 10,835

(Dollars in Thousands)

Fiscal 2027 $ 11,631

Fiscal 2028 9,567

Fiscal 2029 7,621

Fiscal 2030 7,261

Fiscal 2031 7,029

Thereafter 16,895

3 unchanged sentences

Lessor Activity

Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics.

These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products.

Assets on the Company’s consolidated balance sheets classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics.

These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of the Company’s disposable products.

Sales-type leases are not significant.

2 unchanged sentences

The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices.

Operating lease revenue represents approximately two percent of the Company’s total net sales.

Operating lease revenue represents approximately three percent of the Company’s total net sales.

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:

(In thousands) March 29, 2025 March 30, 2024

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Convertible notes $ 688,775 $ 983,951

2 unchanged sentences

Other borrowings 674 809

Less current portion ( 303,558 ) ( 10,229 )

Total Debt 1,224,580 1,224,788

current portion ( 5,015 ) ( 303,558 )

Long-term debt $ 1,219,565 $ 921,230

1 unchanged sentence

On March 5, 2021, the Company issued $ 500.0 million aggregate principal amount of 0.0 % convertible senior notes due 2026 (the “2026 Notes”).

The 2026 Notes are governed by the terms of the Indenture between the Company and U.S.

The 2026 Notes are governed by the terms of an Indenture between the Company and U.S.

Bank Trust Company, National Association, as trustee.

The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased.

HAEMONETICS CORPORATION AND SUBSIDIARIES

1 unchanged sentence

In the first quarter of fiscal 2025, the Company repurchased $ 200.0 million of the aggregate principal amount for $ 185.5 million, resulting in a gain of $ 14.5 million related to the discount on repurchase.

As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $ 1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $ 12.6 million, which was recorded in Interest and other income (expense), net on the Consolidated Statements of Income.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding September 1, 2025 only under the following circumstances:

• During any calendar quarter (and only during such calendar quarter) beginning after June 30, 2021, if, the last reported sale price per share of the Company’s common stock exceeds 130 % of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

• During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2026 Notes for such trading day was less than 98 % of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

• The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10 % of the previous day’s closing sale price;

• Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2026 Notes;

• Prior to the related redemption date if the Company calls the 2026 Notes for redemption.

On or after September 1, 2025, until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2026 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances.

The conversion rate for the 2026 Notes is 5.7033 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $ 175.34 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture.

Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted.

If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2026 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met.

The 2026 Notes were therefore not convertible as of March 29, 2025 and were classified as short-term debt on the Company’s consolidated balance sheets.

The 2026 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after March 5, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100 % of the principal amount of the 2026 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date.

Upon the occurrence of certain fundamental changes involving the Company, holders of the 2026 Notes may require the Company to repurchase for cash all or part of their 2026 Notes at a repurchase price equal to 100 % of the principal amount of the 2026 Notes to be repurchased, plus

accrued and unpaid interest.

As of March 29, 2025, the $ 300.0 million principal balance was netted down by $ 1.5 million of remaining debt issuance costs, resulting in a net convertible note payable of $ 298.5 million.

Interest expense related to the 2026 Notes was $ 1.4 million for

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

fiscal 2025 which is entirely attributable to the amortization of the debt issuance costs.

The remaining debt issuance costs are amortized at an effective interest rate of 0.5 %.

As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $ 1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $ 12.6 million, which was recorded in interest and other expense, net on the consolidated statements of income.

On or after September 1, 2025, until the close of business on the scheduled trading day immediately preceding the maturity date, holders had the right to convert all or a portion of their 2026 Notes.

No holders exercised conversion rights with respect to the 2026 Notes prior to maturity.

Interest expense related to the 2026 Notes was $ 1.5 million for fiscal 2026, which is entirely attributable to the amortization of the debt issuance costs.

On March 2, 2026, the Company repaid in full at maturity its 2026 Notes for an aggregate amount of $ 300.0 million in cash, representing the outstanding principal amount of the 2026 Notes.

The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility.

The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.

On May 28, 2024, the Company issued $ 700.0 million aggregate principal amount of 2.5 % convertible senior notes due 2029 (the “2029 Notes”).

The 2029 Notes are governed by the terms of the Indenture between the Company and U.S.

The 2029 Notes are governed by the terms of an Indenture between the Company and U.S.

Bank Trust Company, National Association, as trustee.

11 unchanged sentences

If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

During fiscal 2026, the conditions allowing holders of the 2029 Notes to convert have not been met.

1 unchanged sentence

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130 % of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100 % of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date.

Upon the occurrence of certain

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100 % of the principal amount of the 2029 Notes to be repurchased, plus

accrued and unpaid interest.

Upon the occurrence of certain fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100 % of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $ 17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0 %.

2 unchanged sentences

In connection with the issuance of the 2026 Notes and the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”).

The 2026 Notes Capped Calls each have an initial strike price of approximately $ 175.34 per share, and the 2029 Notes Capped Calls each have an initial strike price of approximately $ 117.12 per share, both are subject to certain adjustments, which correspond to the initial conversion price of the convertible notes.

The 2026 Notes Capped Calls have initial cap prices of $ 250.48 per share, and the 2029 Notes Capped Calls have initial cap prices of $ 180.18 per share, both subject to certain adjustments.

The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2026 Notes and 2029 Notes, with such offset subject to a cap based on the cap price.

The 2026 Notes Capped Calls cover approximately 2.85 million shares of the Company’s common stock, and the 2029 Notes Capped Calls cover approximately 5.98 million shares of the Company’s common stock, both subject to anti-dilution adjustments.

For accounting purposes, the Capped Calls are separate transactions, and not part of the 2026 Notes and 2029 Notes.

The 2026 Notes Capped Calls each had an initial strike price of approximately $ 175.34 per share, and the 2029 Notes Capped Calls each have an initial strike price of approximately $ 117.12 per share, both are subject to certain adjustments, which correspond to the initial conversion price of the convertible notes.

The 2026 Notes Capped Calls had initial cap prices of $ 250.48 per share, and the 2029 Notes Capped Calls have initial cap prices of $ 180.18 per share, both subject to certain adjustments.

The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2029 Notes, with such offset subject to a cap based on the cap price.

No holders exercised conversion rights with respect to the 2026 Notes prior to maturity, and, in accordance with their terms upon maturity of the 2026 Notes, the Capped Calls related to the 2026 Notes have expired.

The 2029 Notes Capped Calls cover approximately 5.98 million shares of the Company’s common stock, and is subject to anti-dilution adjustments.

For accounting purposes, the Capped Calls are separate transactions, and not part of the 2029 Notes.

As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives.

The cost of $ 88.2 million incurred to purchase the 2029 Notes Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured for the year ended March 29, 2025.

The cost of $ 88.2 million incurred to purchase the 2029 Notes Capped Calls was recorded as a reduction to additional paid-in capital in fiscal 2025 and will not be remeasured.

Credit Facilities

1 unchanged sentence

The amended and restated credit agreement provided for a $ 750.0 million senior unsecured term loan and a $ 420.0 million senior unsecured revolving credit facility (together the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus ranging from 1.125 % to 1.750 % based on the Company’s consolidated net leverage ratio, as specified in the agreement.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029.

7 unchanged sentences

For fiscal 2026, the Company recognized $ 17.6 million of interest expense and amortization of debt issuance costs related to its credit facilities.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

At March 29, 2025, $ 245.3 million was outstanding under the term loan with an effective interest rate of 5.7 %, which was netted down by the $ 5.3 million of remaining debt discount, resulting in a net note payable of $ 240.0 million.

There were no outstanding borrowings under the revolving credit facility at March 29, 2025.

As of March 28, 2026, $ 239.1 million was outstanding under the term loan with an effective interest rate of 5.6 %, which was netted down by the $ 3.9 million of remaining debt discount, resulting in a net note payable of $235.1 million.

In connection with the settlement of the 2026 Notes, the Company borrowed $ 300.0 million under the revolving credit facility, which was outstanding as of March 28, 2026.

The Company also had $ 17.7 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of March 28, 2026.

13 unchanged sentences

The current commitment fee on the undrawn portion of the revolving credit facility is 0.200 %.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Interest expense was $ 19.3 million, $ 35.9 million and $ 19.5 million for fiscal 2026, 2025 and 2024, respectively.

2 unchanged sentences

The future aggregate amount of debt maturities are as follows:

(In thousands)

2026 $ 306,349

Debt Maturities

(Dollars in Thousands)

Fiscal 2027 $ 7,874

Fiscal 2028 12,564

Fiscal 2029 18,818

Fiscal 2030 1,200,073

Fiscal 2031 77

Thereafter 401

Total debt maturities $ 1,239,807

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally.

For the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023 the percent of the Company’s sales generated outside the U.S.

For the fiscal years ended March 28, 2026, March 29, 2025 and March 30, 2024 the percent of the Company’s sales generated outside the U.S.

in local currencies were 26.4 %, 25.7 % and 25.9 %, respectively.

4 unchanged sentences

That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates.

The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Franc, Mexican Peso, Chinese Yuan, and Canadian Dollar.

The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen, Mexican Peso and Euro, and to a lesser extent Canadian Dollar, Swiss Franc and Chinese Yuan.

This does not eliminate the impact of the volatility of foreign exchange rates.

1 unchanged sentence

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of March 29, 2025 and March 30, 2024 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”).

All of the Company’s designated foreign currency hedge contracts as of March 28, 2026 and March 29, 2025 were cash flow hedges under ASC Topic 815, Derivatives and Hedging .

The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs.

2 unchanged sentences

The Company had designated foreign currency hedge contracts outstanding in the contract amount of $ 30.1 million as of March 28, 2026 and $ 23.6 million as of March 29, 2025.

As of March 29, 2025, a loss of $ 1.5 million, net of tax, will be reclassified to earnings within the next twelve months.

As of March 28, 2026, a gain of $ 2.5 million, net of tax, will be reclassified to earnings within the next twelve months.

Substantially all currency cash flow hedges outstanding as of March 28, 2026 mature within twelve months.

3 unchanged sentences

These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month.

They are not designated as cash flow or fair value hedges under ASC 815.

They are not designated as cash flow or fair value hedges under ASC Topic 815.

These forward contracts are marked-to-market with changes in fair value recorded to earnings.

The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $ 89.6 million as of March 29, 2025 and $ 39.9 million as of March 30, 2024.

The Company had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $ 75.3 million as of March 28, 2026 and $ 89.6 million as of March 29, 2025.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Interest Rate Swaps

6 unchanged sentences

The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company held the following interest rate swaps as of March 28, 2026:

Hedged Item Original Notional Amount Notional Amount as of March 28, 2026

Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Fair Value Assets (Liabilities)

(In thousands)

Designation Date Effective Date Termination Date Fixed Interest Rate Estimated Fair Value Assets

(Dollars in Thousands)

1-month USD Term SOFR $ 109,900 $ 100,321 9/27/2024 9/30/2024 4/30/2029 3.3 % $ 859

1 unchanged sentence

Total $ 219,800 $ 199,287 $ 1,771

For fiscal 2025, the Company recorded a gain of $ 0.6 million, net of tax, in accumulated other comprehensive income to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

For fiscal 2026, the Company recorded a loss of $ 0.4 million, net of tax, in AOCL within the consolidated balance sheets to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

Trade Receivables

4 unchanged sentences

The following is a roll forward of the allowance for credit losses:

Twelve Months Ended

(In thousands) March 29, 2025 March 30, 2024 April 1, 2023

Beginning balance $ 5,695 $ 4,932 $ 2,475

Allowance for Credit Losses (Recoveries)

(Dollars in Thousands)

Balance as of April 1, 2023

Credit loss 840

Recoveries ( 77 )

Ending balance $ 6,300 $ 5,695 $ 4,932

Balance as of March 30, 2024

Credit loss 725

Recoveries ( 120 )

Balance as of March 29, 2025

Credit loss 615

Write-offs ( 3,129 )

Recoveries ( 93 )

Balance as of March 28, 2026

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Other Fair Value Measurements

5 unchanged sentences

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Fair Value of Derivative Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of income and comprehensive income for the fiscal year ended March 29, 2025.

Derivative Instruments

Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Loss Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings Location in Consolidated Statements of Income and Comprehensive Income Amount of Gain Excluded from

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in its consolidated statements of income and consolidated statements of comprehensive income for the fiscal year ended March 28, 2026.

Derivative Instruments Amount of Gain (Loss) Recognized in AOCL Amount of Gain (Loss) Reclassified from AOCL into Earnings Classification in Earnings Amount of Gain (Loss) Excluded from

Effectiveness

Testing Location in Consolidated Statements of Income and Comprehensive Income

(In thousands)

Testing Classification in Earnings

(Dollars in Thousands)

Designated foreign currency hedge contracts, net of tax $ 2,540 $ 1,145 Net revenues, COGS and SG&A $ 2,637 Interest and other expense, net

3 unchanged sentences

As of March 28, 2026, no material deferred taxes were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet.

The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities.

ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the consolidated balance sheets.

The Company determines the fair value of its derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures , by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities.

In certain instances, the Company may utilize financial models to measure fair value.

3 unchanged sentences

and inputs derived principally from, or corroborated by, observable market data by correlation or other means.

As of March 29, 2025, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

As of March 28, 2026, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following tables present the fair value of the Company’s derivative instruments as they appear in its consolidated balance sheets as of March 28, 2026 and March 29, 2025:

(In thousands) Location in

Consolidated Balance Sheet As of March 29, 2025 As of March 30, 2024

Classification March 28, 2026 March 29, 2025

(Dollars in Thousands)

Derivative Assets:

Designated foreign currency hedge contracts Prepaid expenses and other current assets $ 1,245 $ 193

Non-designated foreign currency hedge contracts Other current assets 85 154

Designated interest rate swaps Other current assets 1,305 1,673

Non-designated foreign currency hedge contracts Prepaid expenses and other current assets 330 85

Designated interest rate swaps Prepaid expenses and other current assets 823 1,305

Designated interest rate swaps Other long-term assets 947 1,020

$ 2,603 $ 3,242

Total $ 3,345 $ 2,603

Derivative Liabilities:

1 unchanged sentence

Non-designated foreign currency hedge contracts Other current liabilities 63 25

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Total $ 113 $ 496

Fair Value Measured on a Recurring Basis

1 unchanged sentence

As of March 28, 2026

(In thousands) Level 1 Level 2 Level 3 Total

Level 1 Level 2 Level 3 Total

(Dollars in Thousands)

Money market funds $ 90,716 $ — $ — $ 90,716

2 unchanged sentences

Designated interest rate swaps — 1,770 — 1,770

$ 158,916 $ 2,603 $ — $ 161,519

Total $ 90,716 $ 3,345 $ — $ 94,061

Designated foreign currency hedge contracts $ — $ 50 $ — $ 50

1 unchanged sentence

Contingent consideration — — 21,063 21,063

$ — $ 496 $ 2,278 $ 2,774

Total $ — $ 113 $ 21,063 $ 21,176

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

As of March 29, 2025

Level 1 Level 2 Level 3 Total

(Dollars in Thousands)

Money market funds $ 158,916 $ — $ — $ 158,916

2 unchanged sentences

Designated interest rate swaps — 2,325 — 2,325

$ 43,073 $ 3,242 $ — $ 46,315

Total $ 158,916 $ 2,603 $ — $ 161,519

Designated foreign currency hedge contracts $ — $ 471 $ — $ 471

Non-designated foreign currency hedge contracts — 25 — 25

$ — $ 931 $ — $ 931

Contingent consideration — — 2,278 2,278

Total $ — $ 496 $ 2,278 $ 2,774

Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments.

4 unchanged sentences

Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value at Valuation Unobservable

(In thousands) March 29, 2025 Technique Input Range

Fair Value as of

March 28, 2026 Valuation Technique Unobservable Input Range

(Dollars in Thousands)

Revenue-based payments $ 3,076 Monte Carlo Simulation Model Discount rate 3.4 %

Projected fiscal year of payments 2028 - 2030

Regulatory-based payment $ — Monte Carlo Simulation Model Discount rate N/A

Probability of payment 0%

Projected fiscal year of payment N/A

Event-based payments $ 390 Monte Carlo Simulation Model Discount rate 5.8 %

Projected fiscal year of payment 2027 - 2028

$ 17,597 Discount Rate 3.0 %

Projected fiscal year of payment 2027

Fair Value as of

March 29, 2025 Valuation Technique Unobservable Input Range

(Dollars in Thousands)

Revenue-based payments $ 1,214 Monte Carlo Simulation Model Discount rate 6.3 %

Projected fiscal year of payments 2026 - 2028

Event-based payment $ 1,064 Monte Carlo Simulation Model Discount rate 5.8 %

Projected fiscal year of payment 2026 - 2028

The fair value of contingent consideration associated with acquisitions was $ 2.3 million at March 29, 2025 and the total was included in Other long-term liabilities.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The fair value of contingent consideration associated with acquisitions was $ 21.1 million and $ 2.3 million as of March 28, 2026 and March 29, 2025, respectively.

There was $ 17.6 million included in other current liabilities as of March 28, 2026 and $ 3.4 million and $ 2.3 million included in other long-term liabilities as of March 28, 2026 and March 29, 2025, respectively.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:

(In thousands)

Balance at March 30, 2024 $ —

Contingent Consideration

(Dollars in Thousands)

Balance as of March 30, 2024

Acquisition date fair value of contingent consideration 25,000

1 unchanged sentence

Change in fair value ( 23,022 )

Balance at March 29, 2025 $ 2,278

Balance as of March 29, 2025

Acquisition date fair value of contingent consideration 20,673

Payment of contingent consideration ( 9 )

Change in fair value ( 1,879 )

Balance as of March 28, 2026

Other Fair Value Disclosures

The fair values of the 2026 Notes and 2029 Notes as of March 29, 2025 were $ 286.3 million and $ 668.4 million, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

The fair value of the 2029 Notes was $ 662.4 million and $ 668.4 million as of March 28, 2026 and March 29, 2025, respectively, which was determined using the market price on the last trading day of the reporting period and is considered level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), the revolving credit facility, accounts receivable and accounts payable approximate fair value.

RETIREMENT PLANS

9 unchanged sentences

Defined Benefit Plans

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

ASC Topic 715, Compensation — Retirement Benefits , requires an employer to:

2 unchanged sentences

and (c) recognize changes in the funded status of a defined benefit post-retirement plan in the year in which the changes occur.

Accordingly, the Company is required to report changes in its funded status in comprehensive loss on its consolidated statement of stockholders’ equity and consolidated statement of comprehensive income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans.

The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates that are subject to change.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Some of the Company’s foreign subsidiaries have defined benefit pension plans covering substantially all full-time employees at those subsidiaries.

Net periodic benefit costs for the plans in the aggregate include the following components:

(In thousands) 2025 2024 2023

2026 2025 2024

(Dollars in Thousands)

Service cost $ 1,804 $ 1,630 $ 1,316

4 unchanged sentences

Plan settlements 15 ( 104 ) —

Totals $ 1,640 $ 1,341 $ 1,191

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Total $ 1,940 $ 1,640 $ 1,341

The activity under those defined benefit plans are as follows:

(In thousands) March 29,

2026 March 29,

(Dollars in Thousands)

Change in Benefit Obligation:

25 unchanged sentences

Accordingly, that plan has no assets included in the information presented above.

The total asset value associated with the reinsurance contracts was $ 7.0 million at March 29, 2025 and March 30, 2024.

The total asset value associated with the reinsurance contracts was $ 7.3 million and $ 7.0 million as of March 28, 2026 and March 29, 2025, respectively.

The total liability for this plan, which is included in the table above, was $ 7.1 million and $ 7.4 million as of March 28, 2026 and March 29, 2025, respectively.

3 unchanged sentences

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows (in thousands):

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows:

Accumulated Other Comprehensive Loss

(Dollars in Thousands)

Balance as of April 1, 2023

Actuarial gain 2,695

Prior service cost $ 46

Actuarial loss ( 2,157 )

Prior service credit ( 170 )

Balance as of March 30, 2024

Actuarial loss ( 268 )

Prior service credit ( 242 )

Plan settlements ( 89 )

Balance as of April 1, 2023 $ 4,075

Actuarial gain ( 2,157 )

Prior service cost ( 170 )

Balance as of March 29, 2025

3 unchanged sentences

Balance as of March 28, 2026

The Company expects to amortize $ 0.3 million from accumulated other comprehensive loss to net periodic benefit cost during fiscal 2026.

The Company expects to amortize $ 0.3 million from AOCL to net periodic benefit cost during fiscal 2027.

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:

10 unchanged sentences

Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 13, Financial Instruments and Fair Value Measurements , all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the Company’s benefit obligation at March 29, 2025.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the Company’s benefit obligation as of March 28, 2026.

Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments are as follows:

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(In thousands)

Estimated future benefit payments are as follows:

Estimated Future Benefit Payments

(Dollars in Thousands)

Fiscal 2027 $ 1,701

4 unchanged sentences

Fiscal 2032-2036 $ 11,783

The Company’s contributions for fiscal 2026 are expected to be consistent with the current year.

The Company’s contributions for fiscal 2027 are expected to be consistent with fiscal 2026.

COMMITMENTS AND CONTINGENCIES

3 unchanged sentences

Legal costs are expensed as incurred.

Plasma Biometric Information Privacy Act

In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals.

9 unchanged sentences

In the first quarter of fiscal 2025, the Company issued payment of the $ 8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice.

Sensor-Guided Technologies Patent Litigation

During the fourth quarter of fiscal 2024, a complaint was filed in the U.S.

1 unchanged sentence

and IP2IPO Innovations, Ltd.

(together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC).

The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages.

A claim construction hearing in the matter is scheduled to take place in the first quarter of fiscal 2026.

The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint.

The Company recorded loss contingencies related to this matter in the first quarter and fourth quarter of fiscal 2025, which did not have a material impact on its Condensed Consolidated Financial Statements.

During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S.

District Court for the District of Colorado.

The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood p lasma collection patents, as embodied in our NexSys PCS ® with YES ® technology and NexSys PCS with Persona ® technology.

While we will incur costs in the course of pursuing this claim, and the outcome of litigation is inherently uncertain, we believe this is a necessary and appropriate action to safeguard our innovations, protect our intellectual property, and further the growth and development of our business.

Product Recall

(together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of Haemonetics, and Haemonetics (1:24-cv-00206-CFC).

The complaint alleged, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor ® technology, infringed a single patent held by the Plaintiffs and sought both injunctive relief and damages.

The Company recorded loss contingencies related to this matter in the first and fourth quarters of fiscal 2025 and in the first quarter of fiscal 2026, which did not have a material impact on its consolidated financial statements.

In the second quarter of fiscal 2026, the parties entered into a final confidential settlement agreement to resolve the matter, which the court approved, and the Company recorded an immaterial additional loss contingency relating to final settlement of the matter.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S.

and certain foreign jurisdictions.

As of March 29, 2025 , the Company has recorded cumulative charges of $ 6.8 million related to inventory, returns and customer claims associated with this recall.

Substantially all outstanding claims have been paid as of March 29, 2025 .

Plasma Patent Litigation

During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S.

District Court for the District of Colorado (1:25-cv-01409).

The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in the Company’s NexSys PCS ® with YES ® technology and NexSys PCS with Persona ® technology.

On June 26, 2025, Terumo filed a motion to dismiss.

On July 17, 2025 and August 12, 2025, the Company filed amended complaints adding recently issued patents.

On September 2, 2025, Terumo filed a partial motion to dismiss with prejudice claiming that the Company’s asserted patents were invalid under 35 U.S.C.

Terumo has also filed inter partes and post-grant review petitions with the U.S.

Patent and Trademark Office (PTO) seeking to invalidate the asserted patents.

In October 2025, Terumo filed a motion to stay the district court proceedings pending resolution of the PTO petitions.

The Company filed responses opposing Terumo’s motions in November 2025.

Two of the nine PTO petitions have been instituted for further review, and seven of the PTO petitions were denied by the PTO.

During the second quarter of fiscal 2026, the Company filed a complaint against Fresenius Kabi USA LLC in U.S.

District Court for the Northern District of Illinois (1:25-cv-08680).

The complaint alleges that Fresenius Kabi infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in the Company’s NexSys PCS with YES technology and NexSys PCS with Persona technology.

In October 2025, the Company filed an amended complaint to add Fenwal Inc.

and Fresenius Kabi AG as parties to the matter.

In December 2025, Fenwal filed its answer and counterclaims, alleging non-infringement and invalidity of the Company’s asserted patents and alleging infringement by the Company of certain of Fenwal’s U.S.

While the Company will incur costs in the course of pursuing these claims, and the outcome of litigation is inherently uncertain, the Company believes this is a necessary and appropriate action to safeguard its innovations, protect its intellectual property, and further the growth and development of its business.

CAPITAL STOCK

9 unchanged sentences

The total shares available for future grant under the 2019 Equity Plan, as amended and restated and giving effect to the applicable adjustment provisions, were 3,108,477 as of March 28, 2026.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Share-Based Compensation

1 unchanged sentence

The total amount of share-based compensation expense, which is recorded on a straight-line basis, is as follows:

(In thousands) 2025 2024 2023

2026 2025 2024

(Dollars in Thousands)

Selling, general and administrative expenses $ 29,511 $ 25,971 $ 23,662

1 unchanged sentence

Cost of goods sold 1,371 1,818 1,564

$ 29,636 $ 28,332 $ 25,583

Total share-based compensation $ 33,827 $ 29,636 $ 28,332

Stock Options

1 unchanged sentence

Options generally vest in equal installments over a four-year period for employees and one year from grant for non-employee directors.

Options expire not more than 7 years from the date of the grant.

Options expire not more than seven years from the date of the grant.

The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

Forfeitures are estimated based on historical experience.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

A summary of stock option activity for the fiscal year ended March 28, 2026 is as follows:

3 unchanged sentences

Life (years) Aggregate

Outstanding at March 30, 2024 1,067,004 $ 74.86 3.68 $ 16,820

(Dollars in Thousands, Except Share and Per Share Data)

Outstanding as of March 29, 2025 993,587 $ 81.75 3.5 $ 2,249

Granted 227,425 70.05

1 unchanged sentence

Forfeited/Canceled ( 166,850 ) 89.42

Outstanding at March 29, 2025 993,587 $ 81.75 3.50 $ 2,249

Exercisable at March 29, 2025 568,514 $ 83.49 2.38 $ 1,283

Vested or expected to vest at March 29, 2025 914,406 $ 81.47 3.40 $ 2,144

Outstanding as of March 28, 2026 1,017,895 $ 78.74 3.5 $ 45

Exercisable as of March 28, 2026 599,839 $ 79.67 2.2 $ 33

Vested or expected to vest as of March 28, 2026 945,805 $ 78.87 3.0 $ 45

The total intrinsic value of options exercised was $ 0.6 million, $ 6.4 million and $ 12.4 million during fiscal 2026, 2025 and 2024, respectively.

6 unchanged sentences

The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The assumptions utilized for option grants during the periods presented are as follows:

6 unchanged sentences

Restricted Stock Units

Restricted Stock Units (“RSUs”) generally vest in equal installments over a three or four period for employees and one year from grant for non-employee directors.

Restricted Stock Units (“RSUs”) generally vest in equal installments over a three or four-year period for employees and one year from grant for non-employee directors.

The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

A summary of RSU activity for the fiscal year ended March 28, 2026 is as follows:

1 unchanged sentence

Grant Date Fair Value

Unvested at March 30, 2024 338,008 $ 72.52

Unvested as of March 29, 2025 303,003 $ 81.27

Granted 225,738 $ 70.52

1 unchanged sentence

Forfeited ( 41,633 ) $ 78.15

Unvested at March 29, 2025 303,003 $ 81.27

Unvested as of March 28, 2026 329,818 $ 75.69

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested are as follows:

6 unchanged sentences

The grant date fair value of Performance Share Units (“PSUs”), adjusted for estimated forfeitures, is recognized as expense on a straight-line basis from the grant date through the end of the performance period.

The value of these PSUs is generally based on relative total shareholder return which equals total shareholder return for the Company as compared with total shareholder return of the PSU comparison group, measured over a three year performance period.

The PSUs comparison group consists of the Standard and Poor's (“S&P”) MidCap 400 Index.

Depending on the Company’s relative performance during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0 % to 200 %, of the award granted.

If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100 % of the target award, regardless of the Company’s performance relative to the its comparison group.

The value of these PSUs is generally based on (i) rTSR, which equals the total shareholder return for the Company as compared with the total shareholder return of a PSU comparison group and;

(ii) the AAGR of the Company, both of which are measured over a three-year performance period.

For outstanding rTSR-based PSUs, the comparison group for awards granted prior to fiscal 2026 consists of the components of the Standard and Poor’s (“S&P”) MidCap 400 Index and for awards granted in fiscal 2026 consists of the components of the S&P Health Care Equipment Select Industry Index.

For outstanding AAGR-based PSUs, the Company recognizes expense based on the number of awards expected to vest, which requires management to assess the probability of achieving the performance conditions.

This assessment is based on internal revenue forecasts, historical performance, and current market conditions, and is reassessed at each reporting date.

Depending on the Company’s performance under the above-mentioned PSU awards during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0 % to 200 % of the award granted.

If the Company’s total shareholder return for the performance period is negative, then any share payout for rTSR-based PSU awards will be capped at 100 % of the target award, regardless of the Company’s performance relative to the comparison group.

As a result, the Company may issue up to 715,262 shares related to outstanding performance-based awards.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

A summary of PSU activity for the fiscal year ended March 28, 2026 is as follows:

1 unchanged sentence

Grant Date Fair Value

Unvested at March 30, 2024 369,800 $ 94.26

Unvested as of March 29, 2025 335,843 $ 112.10

220,349 $ 87.66

1 unchanged sentence

Forfeited ( 36,495 ) $ 114.24

Unvested at March 29, 2025 335,843 $ 112.10

Unvested as of March 28, 2026 357,631 $ 108.86

(1) Includes 35,443 shares issued for awards vested during fiscal 2026 based on achievement of performance metrics.

(2) Includes the vesting of 226,274 and 7,110 shares that were earned for awards granted in fiscal 2022 for various performance periods ending during fiscal 2025, based on actual relative total shareholder return of 200 % and 176 %, respectively.

(2) Includes the vesting of 162,066 shares that were earned for TSR-based PSU awards granted in fiscal 2023 for performance periods ending during fiscal 2026, representing 128 % of the target award.

The Company uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards with market conditions.

4 unchanged sentences

Correlation of returns 27.81 % 58.08 % 59.93 %

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The weighted-average grant-date fair value of PSUs granted is as follows:

10 unchanged sentences

The purchase price for shares is the lower of 85 % of the fair market value of the common stock at the beginning of the purchase period, or 85 % of such value at the end of the purchase period.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:

5 unchanged sentences

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $ 15.98 , $ 19.13 and $ 20.27 during fiscal 2026, 2025 and 2024, respectively.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended March 29, 2025 and March 30, 2024:

(In thousands) Foreign currency Defined benefit plans Net Unrealized Gain (Loss) on Derivatives Total

Balance, April 1, 2023 $ ( 33,935 ) $ 4,075 $ ( 521 ) $ ( 30,381 )

Other comprehensive (loss) income before reclassifications ( 4,339 ) ( 2,327 ) 4,912 ( 1,754 )

Amounts reclassified from accumulated other comprehensive loss (1)

— — ( 3,497 ) ( 3,497 )

Net current period other comprehensive (loss) income ( 4,339 ) ( 2,327 ) 1,415 ( 5,251 )

The following is a roll-forward of the components of AOCL, net of tax, for the years ended March 28, 2026 and March 29, 2025:

Foreign currency Defined benefit plans Net Unrealized Gain (Loss) on Derivatives Total

(Dollars in Thousands)

Balance, March 30, 2024 $ ( 38,274 ) $ 1,748 $ 894 $ ( 35,632 )

Other comprehensive loss before reclassifications ( 17,974 ) ( 599 ) ( 935 ) ( 19,508 )

Amounts reclassified from accumulated other comprehensive loss (1)

Net current period other comprehensive loss ( 17,974 ) ( 599 ) ( 879 ) ( 19,452 )

Amounts reclassified from AOCL (1)

Balance, March 29, 2025 $ ( 56,248 ) $ 1,149 $ 15 $ ( 55,084 )

Other comprehensive income before reclassifications 16,916 ( 403 ) 2,097 18,610

Amounts reclassified from AOCL (1)

— — ( 1,140 ) ( 1,140 )

Balance, March 28, 2026 $ ( 39,332 ) $ 746 $ 972 $ ( 37,614 )

(1) Presented net of income taxes, the amounts of which are insignificant.

4 unchanged sentences

• Blood Center

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources.

Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income.

These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of our enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures.

These items include acqui sition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, digital transformation costs related to the upgrade of the Company’s enterprise resource planning system, impairments and write downs, costs related to compliance with the European Union Medical Device Regulation (“EU MDR”) and In Vitro Diagnostic Regulation (“EU IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration and unusual or infrequent gains such as on repurchases of convertible notes or divestitures.

Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow.

1 unchanged sentence

The prior period segment disclosures have been recast to reflect the new presentation.

We do not track our assets by segment, and as a result it is not practical to show assets or depreciation by segment.

Consequently, our CODM does not review assets by segment when assessing business performance and allocating resources.

The Company does not track its assets by segment, and as a result it is not practical to show assets or depreciation by segment.

Consequently, the Company’s CODM does not review assets by segment when assessing business performance and allocating resources.

HAEMONETICS CORPORATION AND SUBSIDIARIES

1 unchanged sentence

Selected information by reportable segment is presented below:

(In thousands) 2025 2024 2023

2026 2025 2024

(Dollars in Thousands)

Net revenues:

Plasma $ 524,456 $ 535,431 $ 569,535

1 unchanged sentence

Hospital 588,304 564,269 456,289

Net sales by business unit $ 1,360,824 $ 1,309,055 $ 1,168,660

Total net revenues $ 1,334,027 $ 1,360,824 $ 1,309,055

Significant segment expenses and operating performance:

14 unchanged sentences

Acquisition, integration and divestiture related costs ( 14,155 ) ( 22,904 ) ( 11,249 )

( 22,904 ) ( 11,249 ) 411

Restructuring and restructuring related costs ( 3,218 ) ( 21,158 ) ( 23,588 )

Digital transformation costs ( 21,526 ) ( 20,273 ) ( 15,667 )

Contingent Consideration 23,022 — —

Remeasurement of contingent consideration 1,879 23,022 —

Impairment of intangible assets ( 86,546 ) ( 2,391 ) ( 10,419 )

( 8,394 ) 2,434 ( 15,353 )

2 unchanged sentences

Income before provision for income taxes $ 128,030 $ 212,071 $ 151,865

(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2 ® related charges and gain on divestiture.

(1) Comprised of write downs of certain assets, EU MDR and EU IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, PCS2 ® related charges, gain on divestiture, and a provision for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable.

HAEMONETICS CORPORATION AND SUBSIDIARIES

1 unchanged sentence

Net revenues by business unit are as follows:

(In thousands) 2025 2024 2023

Plasma $ 535,431 $ 569,535 $ 499,916

2026 2025 2024

(Dollars in Thousands)

Plasma net revenues $ 524,456 $ 535,431 $ 569,535

Apheresis $ 220,861 $ 213,134 $ 211,173

Whole Blood 406 47,990 72,058

Blood Center 261,124 283,231 287,034

Blood Center net revenues $ 221,267 $ 261,124 $ 283,231

Interventional Technologies $ 234,007 $ 255,019 $ 174,285

Blood Management Technologies 354,297 309,250 282,004

Hospital $ 564,269 $ 456,289 $ 381,710

Hospital net revenues $ 588,304 $ 564,269 $ 456,289

Total net revenues $ 1,334,027 $ 1,360,824 $ 1,309,055

(In thousands) 2025 2024 2023

Depreciation and amortization

Depreciation and amortization, excluding impairment charges, by business unit are as follows:

2026 2025 2024

(Dollars in Thousands)

Plasma $ 47,368 $ 48,264 $ 45,712

2 unchanged sentences

Total depreciation and amortization (excluding impairment charges) $ 111,717 $ 115,586 $ 97,215

(In thousands) March 29,

2025 March 30,

Long-lived assets (1)

Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:

March 28, 2026 March 29, 2025

(Dollars in Thousands)

Plasma $ 206,365 $ 189,833

2 unchanged sentences

Total long-lived assets $ 305,761 $ 284,052

(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by operating regions is presented below:

(In thousands) March 29,

2025 March 30,

Long-lived assets (1)

Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:

March 28, 2026 March 29, 2025

(Dollars in Thousands)

United States $ 224,699 $ 217,212

4 unchanged sentences

Total long-lived assets $ 305,761 $ 284,052

(1) Long-lived assets are comprised of property, plant and equipment.

HAEMONETICS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(In thousands) 2025 2024 2023

Net revenues by operating regions are as follows:

2026 2025 2024

(Dollars in Thousands)

United States $ 982,176 $ 1,010,918 $ 970,007

6 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 8. Financial Statements and Supplementary Data